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Abstract 
DEEP LEARNING IN PERSONALIZED MEDICINE: APPLICATIONS IN PATIENT 
SIMILARITY, PROGNOSIS, AND OPTIMAL TREATMENT SELECTION 
Beau Norgeot 
 
Two information technology revolutions are colliding in medicine. The first revolution has been 
the digitalization of health data, specifically Electronic Health Records (EHR). These records 
contain the details of who we are as patients, our ailments, treatments, and outcomes. Tragically, 
despite billions of dollars in investment from the US government, hardly any of this data is being 
utilized to better understand medicine or improve healthcare. This is largely because the data is 
voluminous, sparse, complex, and poorly formatted; making it unsuitable for traditional analytics 
methods. However the second revolution, modern Artificial Intelligence, specifically deep 
learning, provides tools, in the form of algorithms, to address exactly these problems. The 
primary difference between these modern algorithms and older ones is that the former are able to 
learn, more or less on their own, how to transform large complex data into a format that makes it 
easier to use and learn from.  
In this dissertation, I have developed methods to apply deep learning to digital health data. Doing 
so, I have shown that we can predict the future health of individual patients with highly complex 
diseases, produced approaches to understand and leverage what these complex models are 
learning, and provided a framework for how healthcare systems of the near future could 
automatically learn to improve care daily.  
For the first time in history, we are in a position to learn from the combined knowledge of tens of 
thousands of physicians and their experiences caring for hundreds of millions of patients. The 
 vi 
potential transformations to healthcare are difficult to fully fathom, but certainly include safer, 
more powerful and efficient medicine, and a rapid speed up in new medical discoveries and 
treatments. Despite the promise, we must proceed carefully, balancing the great need to 
collectively use our data for better medicine with the individual right to privacy.  
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Chapter 1 
Desideratta 
 
1.1. Readme 
This chapter serves as a brief summary of the complete dissertation. Here I will discuss 
the elements of the problem at hand and provide a concise description of each chapter to follow. 
 
1.2. The Checklist 
The problem, in a nutshell, is that human health is highly individual and complex. We 
finally have a large amount of detailed health information (EHRs) to study, but we lack good 
tools to fully utilize it to improve care or learn more about human health and disease. 
Additionally, these data points that we do have are made up of living people who have both legal 
and human rights to privacy, so we must proceed carefully and respectfully. 
Given the above considerations, a checklist to launch this new field of Deep Learning 
Healthcare that would enable the systematic utilization of data on previous actions and outcomes 
to enable smarter ongoing choices, might look something like this: 
1. Identify deep learning approaches to modeling individual patients, which are 
characterized by sparse, lumpy, longitudinal data 
2. Apply those approaches to the simplest, safest task that addresses a meaningful clinical 
problem 
3. Explain how the models are making decisions to foster trust and expand knowledge 
4. Ramp up: Move beyond simple data to address deeper problems with greater granularity 
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1.3. The Following Chapters 
Chapter 2 “Towards a Deep Learning Healthcare System” describes the vision of how the 
intersection of digital health data with modern AI will empower healthcare systems in the near 
future to automatically learn to improve decisions and care daily.  
Chapter 3 “Modeling Longitudinal Electronic Health Records” presents the results of 
detailed algorithmic experiments to identify optimal deep learning approaches to represent 
longitudinal patient data. 
Chapter 4 “Predicting the Future” applies the methodology learned in the previous 
chapter and applies it to the problem of forecasting future individual health outcomes for patients 
with Rheumatoid Arthritis, a complex auto-immune disease.  
Chapter 5 “MI_CLAIM”, or Minimum Information for Clinical Artificial Intelligence 
Modeling studies, establishes a standard for designing, recording and reporting AI-based clinical 
informatics studies. This will, in turn, facilitate transparency and the establishment of trust and 
ultimately enable the utilization of such models in the clinical setting. 
Chapter 6 “MAgEC”, Model Agnositc Effect Coefficients, offers a single, easily 
interpretable, method to analyze how any machine learning model (from logistic regression, to 
random forests, to deep neural networks) is making decisions. It provides global and local 
explanations and enables the direct comparison of what multiple different models have learned 
from the same data. 
Chapter 7 “DeepMANN” is an inflection point, here we begin to move into data of 
greater complexity as I demonstrate that the combination of feature selection and relatively 
simple deep networks can be taught to identify clinical phenotypes from microarray data with 
accuracy that rivals or exceeds substantially more complex approaches. 
 3 
Chapter 8 “Philter”, Protected Health Information Filter, opens up the potential to mine 
the richest information in the EHR, physician notes, by providing an algorithm that removes 
patient-specific information from each note, leaving only the relevant medical information about 
the patient’s condition, treatment, and response. 25,000 randomly selected notes (the largest such 
corpus in the world) were marked for PHI, word for word, by a team of trained expert annotators.  
Chapter 9 “Deep Cumulative Dosage Information” details the process by which deep 
learning can be used in the Natural Language Processing space to automatically determine the 
total cumulative dose of a steroid that a patient has received directly from the EHR ‘Sig’ field. 
Cumulative steroid use is associated with several serious health conditions and is also an 
important surrogate outcome for auto-immune treatments. 
Chapter 10 “Medical Research Topic Labeling” illustrates early successes of employing 
deep learning to automatically annotate complex medical datasets, making important information 
easier to find and reducing potential sources for labeling-error. 
Chapter 11 “Conclusions” provides the summary and concluding thoughts on the overall 
paper.  
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Chapter 2 
Towards A Deep Learning Healthcare System 
 
 
2.1. Permissions 
This Chapter was originally published in Nature Medicine (Nature Medicine volume 25, 
pages14–15 (2019) and is reproduced here with permission. 
 
2.2. Call For A Deep Learning Healthcare System 
We are currently witnessing two incredible information-technology revolutions colliding 
in medicine. Electronic health records (EHRs) are capturing the thoughts, orders, images, and 
outcomes of the best trained physicians. Advances in machine learning are beginning to 
supplement clinical medicine. But breakthroughs still remain fully unrealized because these 
revolutions are siloed. While the raw materials exist to learn from current actions and outcomes 
in medicine, they are not systematically utilized to improve the practice of medicine.  
Nearly every other industry uses data on previous actions and outcomes to enable smarter 
ongoing choices. Amazon targets product recommendations based on similar customers’ 
shopping patterns. Google updates its searches based on the outcomes of previous searches. 
Waze uses information on drivers traveling similar routes to optimize directions. 
Why is medicine, as an industry, still left out? 
The roadblocks to bringing medicine into the data-driven era are operational and cultural. 
While many have written about inefficiencies in the US medical system relative to rising 
healthcare spending1 and the challenges in improving quality2, the US medical system is a 
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competitive one, meaning competitors are incented not to fully share data, pricing, and costs. 
There is a significant room for improvement, and potential to better use the data we do have. 
While EHRs have known challenges3,4, they now represent the legal medical record and 
are complete enough to enable another physician to completely care for a patient. This data is 
perhaps among the most expensive in the US, given that physicians are paid to enter much of it. 
Of course, EHR data must only be used in safe respectful ways, but it will be a tragedy if this 
data is not used to improve the practice of medicine. 
Over ten years ago, Lynn Etheredge5 and others6 proposed the Learning Health System, 
where millions of EHRs could be used to inform medical practice and policy. But these 
visionaries were still proposing a system in which physicians mediate the learning. Now with 
nearly 80% of medication orders captured electronically and more than 1.7 billion prescriptions 
per year electronically tracked7, combined with 98% of hospital systems now using EHRs8, we 
can envision computer systems that learn how to improve the medical system by themselves. 
It is now time to safely bring huge medical data repositories and advanced learning 
algorithms together with physicians to make a Deep Learning Healthcare System (see Figure 
2.1). Deep learning (DL), the newest iteration of machine learning methodologies, is now 
performing at state-of-the-art levels in previously difficult tasks, including image analysis, 
language processing, information retrieval, and forecasting. DL is well suited for medical data as 
it can identify patterns in sparse, noisy data, and requires little input feature engineering. Current 
successes have shown performance that meets or surpasses experts, but perhaps more 
importantly, they can be run in real-time within or across entire hospital systems. We propose 
that future physicians will be armed with insights from models continuously trained and updated 
 6 
on real-world clinical data to make more accurate diagnoses and individually optimized 
treatment decisions. 
Is there one optimal way to practice medicine? Imagine ten physicians faced with a single 
clinical conundrum (choice A, B, or C) on one patient. If these ten were provided with the 
maximum possible information about a patient in a clear format, from physical exam to 
preferences, the world’s literature, and data on similar patients, should all ten physicians reach 
the exact same choice for this clinical decision? We know today they probably would not, but 
shouldn’t they? If the answer is yes, then medicine is fundamentally machine learnable. 
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Figure 2.1: A Deep Learning Healthcare System 
 
Figure 2.1: (1) The EHR contains the record, in digital form, of the demographics, symptoms, vitals, labs, and 
diagnoses of each of the individual patients that have been seen as well treatment decisions made by their physician 
and often the resulting outcomes for the patient. (2) The amount of data that a physician must synthesize in one visit 
in order to make decisions is large and growing. Deep Learning can identify complex patterns in patients, 
treatments, and outcomes in an automated manner in near-real-time, distilling them into individualized 
recommendations for physicians based on real-world data. (3) Physicians can review the Deep-Learned 
recommendations, comparing it to their own knowledge and experience, then discussing the options with their 
patient before finalizing a decision. The system is iterative in nature, improving with every patient-physician 
interaction. 
 
Many health conditions present in heterogeneous ways, making it challenging to establish 
an accurate diagnosis over time. The treatment regimens for many complex conditions require 
physicians to stay aware of the latest options and evidence. A Deep Learning Healthcare System 
would enable all physicians to practice at the same level of expertise as a panel of the very best 
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physicians. Since deep learning models could be shared between hospitals without the privacy 
risks of sharing patient data, the potential is nearly limitless to create a new system of precision 
medicine learned from the decisions and outcomes of diverse physicians treating diverse 
patients. 
Fogel & Kvedar9 have insightfully noted that bringing AI to medicine will not sideline 
doctors, but will instead enhance their strengths. Physicians, empowered by patterns and 
evidence derived from large-scale real-world data, will be able to focus on the uniquely human 
elements of their profession for which they are best trained. Tasks which cannot be performed by 
a machine because they require emotional intelligence, such as asking careful questions of the 
patient to uncover more nuanced symptoms, and building trust through personal relationships by 
using human intuition, will still be unique qualifications of physicians to guide the 
implementation of the computationally optimized diagnoses and treatment plans of the future. 
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Chapter 3 
Modeling Longitudinal Electronic Health Records 
 
 
3.1. Permissions 
Portions of this chapter was originally published in NeurIPS 2018 and JAMA Network 
Open (JAMA Netw Open. 2019;2(3):e190606) and is available under a Creative Commons 
license.  
 
3.2. Time aggregation and model interpretation for deep multivariate longitudinal patient 
outcome forecasting systems in chronic ambulatory care 
Clinical data for ambulatory care, which accounts for 95% of the nations healthcare 
spending, is characterized by (relatively) small sample sizes of longitudinal data, unequal 
spacing between visits for each patient, with unequal numbers of data points collected across 
patients. While deep learning has become state-of-the-art for sequence modeling, it is unknown 
which methods of time aggregation may be best suited for these challenging temporal use cases. 
Additionally, deep models are often considered uninterpretable by physicians which may prevent 
the clinical adoption, even of well performant models. Using EHR data on a complex 
autoimmune disease from 2 hospital systems with highly diverse patient populations, we show 
that time-distributed-dense layers combined with GRUs produce the most generalizable models 
and we provide a framework for the clinical interpretability of the models. 
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3.2.1. Introduction 
Chronic ambulatory disease care is associated with the overwhelming majority of death, 
disability, and healthcare spending Buttorff et al. (2017), for Medicare & Medicaid Services et 
al. (2016) in the United States. Successful predictive modeling in this setting has the potential to 
significantly improve clinical care, patient quality of life, and healthcare efficiency. Identifying 
the best methods and functions for time aggregation will be a critically important part of building 
models that perform well in these types of settings. However, even well performant models may 
not be sufficient to warrant the clinical adoption of artificial intelligence (AI) to longitudinal 
patient care. Deep learning has traditionally been met with resistance in the clinical community 
due to a general sentiment that the models function entirely as uninterpretable black boxes. 
While we agree that the use of black boxes in clinical care should be avoided wherever possible, 
we posit that deep time series models need not be black boxes at all.  
By transferring and extending a traditional method to calculate variable importance in 
machine learning models known as Permutation Importance Scoring Breiman (2001) to deep 
time series modeling and by developing a method of visualizing the final model-learned patient 
representations as clusters we aim to show that it is possible to interpret the driving factors 
behind model predictions on both the patient and population levels. These methods can not only 
contribute to model interpretation but could be used in the future to generate and test medical and 
pharmaceutical hypotheses in this space in which individual progression and response to 
treatment for many of the diseases may not be well understood.  
We selected Rheumatoid Arthritis (RA) as a use case. RA is a common (1% nationwide) 
complex chronic autoimmune disease with unknown causes along with highly individualized 
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responses to therapeutics and disease progression. It is associated with significant morbidity and 
a high cost of care. Our goal was to examine the impact of time aggregation strategies on deep 
time series models which used a patient’s history of labs, medications, and disease activity along 
with their current Machine Learning for Health (ML4H) Workshop at NeurIPS 2018. 
arXiv:1811.12589v1 [cs.LG] 30 Nov 2018 treatment plan and current clinical measurements to 
forecast whether a patient’s disease activity would be controlled or uncontrolled at their next 
visit. The highest performing model was then examined for interpretation using the approaches 
described above.  
 
3.2.2. Methods 
Electronic Health Record (EHR) data were extracted from two rheumatology clinics with 
significantly different patient populations and provider treatment patterns, a University Clinic 
(UC) and a public Safety Net (SN). Patients from the larger UC cohort (n=578) were split into 
three groups [train (n=369), validation (n=93), test (n=116)] using stratified random sampling on 
the primary outcome which was the binary category of controlled or uncontrolled disease activity 
at their most recent clinical visit. Patients from the smaller SN cohort (n=242) were split into two 
groups, train (n=125) and test (n=117) using stratified random sampling as previously described. 
The patient data were grouped into three windows of one hundred days each (which corresponds 
to the median number of days between visits) to overcome unequal length of time between visits. 
Data within each window was further aggregated, se Relative Difference = (mean(permuted 
score) - original score) / (original score) 
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3.2.2.1. Population Differences 
We generated a graphic, which we have called a Confusion Plot, by extracting the final 
dense representation learned by the fully trained model for each patient and plotting them using 
T-SNE, colored by outcome category, to assess the coherence of the representations learned by 
the model. We performed this experiment for each cohort and compared the results side by side 
to determine the differences in patient representation for the model in each patient population. 
 
3.2.3. Results 
3.2.3.1. Time Aggregation 
Results from the time aggregation experiment can be found in Table 3.1. Using a Time 
Distributed Dense (TDD) layer as the input layer provides the single largest increase in 
predictive performance as seen by the relative difference between the TDD and Dense 
architectures. Using a convolutional layer with non-causal padding after the TDD provides a 
modest improvement over a dense layer, while using causal padding increases performance even 
further. The top performing architectures used a recurrent layer following the TDD with GRUs 
outperforming LSTMs.  
 
Table 3.1: Time Aggregation Experiment Results 
Function Dense 
TDD 
Dense 
TDD GRU 
TDD 
LSTM 
TDD CNN 
TDD 
Causal 
CNN 
AUC 0.778 0.817 0.845 0.838 0.821 0.832 
95% CI 
[0.683, 
0.864] 
[0.731, 
0.894] 
[0.753 
,0.914] 
[0.743 
,0.911] 
[0.727, 
0.897] 
[0.740, 
0.906] 
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3.2.4. Interpretability 
3.2.4.1. Longitudinal Permutation Importance Scoring 
More recent time windows are more important than more distant time windows. CDAI 
history is of greatest importance followed by steroid prescription (Prednisone, a reasonable 
surrogate for all steroids representing 55% of steroids prescribed in our data set). Changing a 
patient’s previous DMARD treatment strategy at the visit prior to the most recent visit was of 
significant performance as were the presence or absence of certain specific DMARDs (See 
Figure 3.1).  
 
Figure 3.1: Permutation Importance Scores 
 
3.2.4.2. Confusion Plot 
In both the UC and SN populations the final patient representations that the model 
learned formed a one-dimensional manifold (a curve). The model is clear in both clinics about 
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patients that will definitely be at one end of the disease activity spectrum or the other at their 
next clinical visit. However, the confusion plots are clearly different between the two 
populations. In the UC cohort (see Figure 3.2), the presence of Controlled and Uncontrolled 
patient representations mix in just one pocket of close proximity to each other in the middle of 
manifold, while within the SN Clinic cohort there are multiple of these highly proximus 
representations that begin to occur in pockets much closer to the tails. 
 
Figure 3.2: Confusion Plots 
 
3.2.5. Discussion and Conclusions 
In this study, we compared different time aggregation functions for ambulatory outcome 
forecasting and provided a framework for interpreting models in this setting. We found that 
using a time distributed dense layer (which uses the same function to re-weight input features 
across all time windows), followed by recurrent modeling of the re-weighted windows produced 
the best results. Longitudinal Permutation Importance Scoring reveals that newer time points are 
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most important, and that recent disease activity scores are important but that quantitative 
inflammatory markers are not. Prescription of new steroids at the current visit, which we 
interpret to clinically indicate currently uncontrolled disease, and maintaining or switching to a 
new DMARD, we interpret to act as surrogate for the patient and physician believing that the 
current DMARD is working, are also important. There are some findings such as the influence of 
certain DMARD changes and steroids additions that require further examination to determine 
whether these finding may lead to new treatment strategies or are the result of confounding by 
indication. A potential limitation of the Longitudinal Permutation Importance Scores as 
implemented in this paper is a lack of directional effect between future disease activity and each 
variable within each window. This could be solved be reporting the changes in probability 
instead of the changes in auROC associated with each permutation, though additional 
considerations will need to be made for the continuous variables.  
An additional straightforward application of directional longitudinal permutation 
importance scoring would be to permute medication choices to optimize probabilities for a 
successful outcome. Examining the Confusion Plots in the current study, the single mixed patient 
pocket at the UC seemed to indicate a natural transition between patients who have Controlled 
and Uncontrolled disease state at their next visit, while the multiple mixed pockets for the SN 
patients perhaps indicates that strong confounding factors are driving outcomes for many 
patients. Since the patients in the SN cohort, unlike those in the UC, are known to be 
predominantly non-White and be considerably less likely to have private insurance, these 
findings support suspected social determinants of health within the population that should be 
further examined.  
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In summary, Longitudinal Permutation Importance Scores can be extended from 
traditional machine learning approaches into longitudinal deep learning methodologies, 
providing insight into variable significance over time. Confusion Plots, which visualize model-
learned dense patient representation vectors, can used to search for sub-cohorts, indicate the 
presence of potential confounding factors, and examine differences between subgroups and 
populations. Taken together, we found that longitudinal deep learning can be successfully 
applied to ambulatory disease forecasting and that the resulting models can be interpreted in a 
straightforward manner. We expect that these methods will be used to facilitate the adoption of 
deep learning in the field of clinical medicine.  
 
3.3. Supplementary Methods 
3.3.1. Data 
3.3.1.1. Primary Cohort (UCSF) 
In order to use real-world longitudinal patient data to build and evaluate our models, we 
utilized the resources made available by the UCSF Clinical Data Research Consultations Team. 
Each day the team extracts the EHR data from Epic Chronicles into the Epic Clarity relational 
database (RDB). A subset of that RDB is used to update the Epic Caboodle data warehouse. The 
Caboodle data is then de-identified using the Safe Harbor method: Private information such as 
names and addresses are removed. Key personal identifiers are replaced with randomly assigned 
surrogate identifiers. Dates are shifted by a random number of days from 0 to -364 so that the 
true date is known no more precisely than the year, however date shifts are kept consistent for 
each patient so that their chronology is accurately maintained. Ages are adjusted so that patients 
> 90 years old are presented as 90 years old. Once a month, the de-identified data is extracted to 
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a set of delimited flat files, which our group stands back up into a SQL database. This database 
contains longitudinal information on over 900,000 individual patients dating from January 2014 
to the present. 
 
3.3.1.2. Replication Cohort (ZSFG) 
The IRB for ZSFG did not require de-identification of patient records. EHR data were 
directly accessed using the eCW product “eBO reports” which runs on an IBM Cognos platform. 
 
3.3.1.3. Variables Utilized in Model 
Given the relatively small number of patients available and the complexity of time series 
models, we chose to only include variables with known clinical significance in the models. These 
variables are known to be associated with disease activity, however no study that we are aware 
of has shown them to be predictive of future disease activity. This approach reduces the risks 
associated with including all variables in the EHR, including under-fitting (inability to separate 
signal from noise) or over-fitting (confusing noise for signal). We include the following: prior 
CDAI, ESR and CRP, DMARDs (Supplementary Table 3.2), oral and injected glucocorticoids, 
autoantibodies (presence of rheumatoid factor [RF] and/or anti-cyclic citrullinated peptides [anti-
CCPs]), and demographics (age, sex, race/ethnicity). Medication names were standardized by 
first using the R scripting library MetaMap1 and then programmatically removing any remaining 
characters associated with delivery or dosage. Medication names were then mapped to the list of 
DMARDs. Steroids were included if their pharmaceutical class was labeled as 
“glucocorticosteroid” in the EHR and their route of administration was either oral or injection. 
All patient medications that did not map to either a DMARD or steroid were dropped. Most 
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machine learning libraries, including the TensorFlow2 library that we planned to use for 
modeling, do not accept string values within tensors. Therefore, we encoded medications using a 
dictionary mapping the drug name to a unique integer value (e.g., Methotrexate= 1) in each 
patients record. We chose to include only the first occurrence of each medication given the lack 
of reliable medication stop dates in the EHR. 
 
3.3.1.4. Modeling Input Formats 
We considered two different formats for representing a patient’s longitudinal trajectory as 
input for modeling. The first method was a Sequential string of events. In this format each 
patient’s events follow the exact chronology in which they appear within the EHR. As an 
analogy, in this format a patient’s trajectory is like a sentence and the goal of the model is to 
predict the final word the sentence (always a CDAI score in this case of either controlled or 
uncontrolled). The potential advantages to this format are based on its flexibility: A patient’s 
trajectory is presented to the model in the exact order that it occurred in the hospital, each patient 
can have an arbitrary number of types of variables, time between patient events can be modeled 
with fidelity, differences in the numbers, types, and order of patient events can be easily 
represented for each individual patient. The potential disadvantage of this format is also related 
to its flexibility: different patients will have different numbers of events and therefore potentially 
drastic differences in the length of their trajectories which necessitates a more complex model 
capable of handling the longest and most complicated sequence. From a back-propagation 
perspective, longer sequences fed into an RNN increase the likelihood of encountering a 
vanishing gradient thus hindering the models ability to learn. Within this format the order of 
variables cannot be anticipated for each patient. Therefore, we prepended the raw values for each 
 20 
variable with a string containing the name of the variable. For example a raw CDAI score of 10 
was converted into ‘cdai10’. Each unique string was then mapped to a unique index. To address 
the loss of ‘nearness’ introduced by converting continuous variables into uncorrelated strings, we 
added an embedding layer to all Sequential architectures. Ideally, this would not only allow the 
network to learn that cdai10 was more similar to cdai11 than cdai50, but also that low CDAI 
scores were more similar to high ESR or CRP values that appear in close longitudinal proximity 
for patients. 
 
Example Sequential format: 
• Conceptual: (event1_type_value, dT1, event2_type_value, dT2,eventn_type_value) 
• Using Real Variables: (ESR11, CRP22, ESR24, methotrexate, CDAI21, PROM50) 
 
The second input format that we explored was to force our data to conform to sliding 
time windows of a fixed interval as is done with traditional Time Series forecasting. In this 
format, a window interval is decided upon (for example, 3 months) and variables are decided (for 
example CDAI, Steroids, CRP). In each window, a single value is entered for each variable. This 
format is almost universally employed for fields in which variable recording can be guaranteed 
to be consistent at specific time intervals, such as the stock market or EKG measurements. 
Outpatient care is by nature inconsistent in the frequency of a patients visits to their care provider 
and the number of variables that are measured for the patient at each visit. This inconsistency is 
the result of a combination in patient adherence, the individual and cyclic nature of chronic 
disease and its severity, and provider preference the types and frequency of measuring patient 
variables and changing treatment strategies. When the sampling frequency and variable 
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measurement is inconsistent, such as for patients with RA (chronic disease), strategies must be 
employed to deal with the cases of either having no history of a variable within a given window 
or having more than one value present for a variable within a single window. Missing values 
were imputed with zeros since the field of deep learning has learned empirically that neural 
networks learn to ignore zero-values assuming that they do not legitimately occur as real input 
values, which is true for our data. Additionally, there is no sensibly accurate method for imputing 
the variables that we have selected as they can change drastically over time within a person and 
have only modest correlation to each other at best. Attempts at non-zero imputation were likely 
to induce spurious correlations, injecting noise into the signal, especially when considering our 
the relatively small size of our training cohort. Since our goal was to predict the most recent 
event, if multiple values occurred for a given variable within a single time window, we selected 
the most recent value. If a patient’s clinical history was too short to fill all windows for a 
particular experiment, all values for that patient’s window were replaced with zeros. 
 
3.3.1.5. Longitudinal Modeling using Deep Learning 
Since patients and their outcomes change over time, and deep RNNs have previously 
demonstrated superior performance to traditional machine learning methods for chronological 
EHR data3, we focused on deep learning models but experimented with many different possible 
ways to represent time dependencies. 
Unlike Random Forests, Support Vector Machines, or Linear Regression, there is no 
discrete Deep Learning algorithm. Deep Learning is a term used to describe machine learning 
models based on neural networks of multiple layers and algorithms for their optimization such as 
stochastic gradient decent and its derivatives. Each layer is composed of a varying number of 
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nodes. The manner in which the nodes operate and are connected to nodes in other layers 
determines the how the layer transforms the input it receives into the output that it generates. 
Deep Learning can be viewed as a hierarchical transformation of the input data, each layer acting 
as a distinct function changing the data in a different way, into the representation of the original 
input data that makes the predictive task as straightforward as possible. An architecture is an 
arrangement of layers placed together and representing either the modeler’s theory or an 
experimental finding about which functions will generate the best representation of the input for 
a given problem.  
 
3.3.1.6. Overview of Relevant Deep Learning Layer Types 
We considered 5 potential layer types to represent patient longitudinal trajectories: 
Dense, Time-Distributed, Convolutional, and Recurrent (LSTM, GRU). Each of these layers 
have distinct methods for generating representations of their input data. Dense layers have no 
representation of chronology or proximity. Therefore, neither the order of patient events nor 
which events happened close in time for a patient can be represented. In this way, models 
composed entirely of dense layers, known as Multilayer Perceptrons, are conceptually similar to 
Random Forests or kernelized regression. Time-Distributed layers learn a single dense mapping 
function that is applied to every timestep of the input data. In our case, this can be thought of as a 
generating one representation for each encounter or window. Convolutional layers can represent 
proximity but not chronology. Therefore, the representations that they generate can account for 
which events happened close in time for a patient, but not the global order of events for a 
patient’s trajectory. Models composed of Convolutional blocks, known as Convolutional Neural 
Networks, offer a distinct advantage in that they use a local pooling of proximity values to 
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reduce the size of the input space, thus reducing the complexity of the model and in-theory 
increasing its ability to generalize. Despite lacking an explicit ability to directly represent the 
order of sequences, CNNs have shown to work very well as language models4, including 
extracting information from clinical text5. LSTMs and GRUs are different variations of 
Recurrent Neural Networks (RNN), which are the family of architectures that explicitly model 
chronological sequences of events. LSTMs and GRUs have slightly different mechanisms for 
learning sequential representations which can lead to differences in performance on different 
data sets. In general, LSTMs are more robust but due to that they are slower to train. 
 
3.3.1.7. Model Training 
The UCSF cohort was divided into three sub-cohorts for model building and testing: 
training, validation, and testing. To ensure that the sub-cohorts were representative of the overall 
population, we calculated the proportion of patients in each CDAI outcome category (60% were 
Controlled, 40% were Uncontrolled). We then performed a Stratified Random Split, keeping 
20% (n = 116) of the patients aside for testing (these patients’ data were never trained on, the 
data was used only to test the final model) and using 80% for model training and development. 
We then performed an additional stratified random split on the patients assigned, allocating 80% 
for direct model training (n = 369) and the remaining 20% (n=93) for model validation. This 
validation cohort was used to assess the generalizability during the model selection process (by 
varying model architectures and hyperparameters). All continuous variables (CDAI, ESR, CRP) 
were then linearly scaled to range between zero and one with min/max scaling using the 
minimum and maximum values for each of these variables found in the training cohort. Thus, the 
training data were used for model optimization and the validation data were used to guard 
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against overfitting during model selection and hyperparameter tuning. Once a final model was 
produced, we combined the validation cohort with the training cohort to train the model on both 
cohorts before the final single evaluation on the test cohort.  
The ZSFG patient cohort was less than half the size of the UCSF cohort and we chose not 
to involve it in model selection. The ZSFG cohort was split in two, the test cohort was matched 
to the size of the UCSF test cohort as closely as possible (n=117) so that model performance 
could be evaluated across equally sized patient populations. A training cohort, comprised of the 
remaining patients (n = 125), was created from the remaining patients. Membership in the 
cohorts was assigned through a random stratified split as described above. 
The goal of any deep learning architecture is to learn a representation of the original input 
data that maximizes the success rate for the predictive task. In this case, the input data is each 
individual patients’ clinical RA trajectory and the task is to predict what each patients’ disease 
activity state will be at their next visit. The final representation that the architecture generates is 
captured by a vector which represents the patients chronology, which we have called a Patient 
Trajectory Vector (PTV). During training, the deep learning architecture is used to generate a 
PTV. The PTV is fed into a logistic classifier which makes a binary prediction (controlled, 
uncontrolled) of the patient’s disease state at the time of their next visit. The difference between 
the sigmoidal prediction of the outcome and the patient’s actual outcome is the error. The error is 
then back-propagated into the PTV and then into the architecture itself. The parameters for the 
architecture are then gently updated in directions that would have led to a better PTV 
representation for that patient resulting in a sigmoidal output closer to the ground truth (zero for 
Controlled, one for Uncontrolled). These updated transformations are then applied to next 
training patient sample and evaluated. In practice, models are updated based on the results of 
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batches of samples instead of single samples because batch-training has been shown to produce 
models that converge faster6.  
For models that included both patient variables that changed over time, such as lab values 
and CDAIs, and static variables that did not change over time, such as demographics, the 
variables were separated according to whether or not they were time-dependent. These separate 
inputs for each patient were fed into two independent deep networks; a recurrent network for the 
time-dependent variables and a purely dense network for static variables. The two network 
outputs were concatenated to form a final joint representation and passed to the logistic 
classifier. Back propagation flowed through both networks allowing joint learning of static and 
time-dependent representations. 
There are many different strategies that can be applied for model optimization. The most 
common methods for optimization include: experienced intuition, grid searches, random 
searches, or some form of Sequential Model-based Global Optimization (SMBO) techniques. 
Since, to our knowledge, no model architectures for multivariable time series deep learning to 
predict future health outcomes for a chronic disease have been published, there was no data to 
guide intuition for selecting the optimal variables. While grid searches are popular because they 
are easy to conduct, Bergstra and Bengio7 have shown that it is more efficient to randomly 
search through values while employing a method to intelligently narrow the search space than it 
is to loop over a fixed sets of hyperparameter values in a grid. SMBOs are algorithms that begin 
with a random search over the hyperparameter space, and then use the results of the models built 
with that search to fit one or more surrogate functions that describe the relationship between a set 
of possible hyperparameters and model generalization. The algorithm then begins optimizing the 
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surrogate function with the goal of identifying points in the hyperparameter space that will lead 
to improved model performance on data unseen by the model during training. 
Our goal was not only to identify the best performing single architecture and 
hyperparameters, but also to uncover trends in performance associated with different ways of 
representing patient trajectories and the types of patient variables that were most essential for 
accurate predictions of future patient outcomes. Therefore, we set up separate SMBO 
experiments for each combination of architecture family: dense, time-distributed, convolutional, 
and recurrent architecture as well as architectures combining different layer types. Once the best 
combination of patient value types and model architecture was identified, additional experiments 
were performed to determine the impact of the length of patient history to include as input on 
model performance. Overfitting, the substantial divergence of model log-loss performance 
between data used for training and unseen data, was rigorously monitored by comparing the 
model’s performance on the training cohort to that of the development cohort. Training for any 
model was stopped as soon as overfitting was detected. Models were ranked by their 
generalization or hold-out accuracy on the development cohort, their performance on the training 
data was never recorded. Model training, optimization, and selection were performed using the 
TensorFlow2 computational engine wrapped with Keras8 as a front end on Amazon Web 
Services Elastic Cloud (EC2) P2XLarge Linux GPU servers. Additional python libraries were 
used for data preprocessing and model evaluation including Pandas9, Matplotlib10, scikit-learn11, 
and Numpy12. 
 
 
 
 27 
3.3.1.8. Transfer Learning and Fine Tuning 
Transfer Learning is the deep learning practice of taking a model that has been fully 
trained on one data set and updating the model’s parameters by retraining the final dense layer on 
data from a new data set while keeping the rest of the model parameters frozen. This is generally 
considered most appropriate when the two datasets are highly similar. For our work, that meant 
training the model on the UCSF data, then updating the weights for the PTV using the training 
cohort from ZSFG while keeping the Time-Distributed Dense and GRU layers frozen.  
Fine Tuning is a general case of Transfer Learning where layers other than the final dense 
layer of a model, including potentially all layers, are updated by training on a new data set. This 
approach is generally most applicable when the two data sets are part of the same general domain 
but are otherwise very different from each other. We experimented successively unfreezing one 
additional layer from the top down. 
 
3.3.2. Supplemental Discussion 
Deep Learning is notorious for requiring training sample sizes far above the number of 
EHR records for patients with most chronic diseases (even if patients at many large hospitals 
were aggregated). To overcome this, during our model building process we leveraged physician 
knowledge and experience to select a small number of raw variables with known clinical 
importance. This reduced the number of variables the model needed to sift through to learn from, 
and presumably reduced the number of patient samples necessary to properly train models, by 
many orders of magnitude. We found that beginning with a small number of clinically important 
variables, even if the consequences of their complex time-dependent interactions are not 
perfectly understood, has the added benefit of increasing model interpretability. 
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The deep neural architecture that performed best was constructed in a way in which a 
human might approach the problem. The time-distributed layer essentially creates a summary of 
each time-window for the patient. The recurrent units then look for longitudinal patterns in the 
chronological summaries from each patient. The dense PTV then generates a single 
representation of the patient’s overall trajectory. It is this complete trajectory representation that 
the logistic classifier uses to forecast the patient’s future CDAI category. The fact that this model 
also contained the smallest number of trainable parameters and utilized a high degree of 
regularization also makes sense intuitively, especially considering the relatively small size of the 
training cohort and the large differences between the two testing cohorts. 
 
3.3.3. Supplementary Tables 
Supplemental Table 3.1: Contrastive Comparison of Machine Learning Methods 
ML 
Method 
Models 
Time 
Interactions 
Unequal 
Length 
Inputs 
Can 
handle 
missing 
data 
Can handle 
high 
dimensions 
Number of 
training 
samples 
needed 
Potential 
to overfit 
Cox Yes No No No No Low Low 
Random 
Forest 
No Yes No Yes No Low Low 
LASSO No No No No Yes Medium Medium 
RNN Yes Yes Yes Yes Yes High High 
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Supplemental Table 3.2: List of medications identified for RA treatment and considered 
DMARDs for the purposes of this work  
Drug Name Class 
Methotrexate Small Molecule 
Sulfasalazine Small Molecule 
Hydroxychloroquine Small Molecule 
Leflunomide Small Molecule 
Azathioprine Small Molecule 
Auranofin Small Molecule 
Chloroquine Small Molecule 
Cyclophosphamide Small Molecule 
Cyclosporine Small Molecule 
Gold Small Molecule 
Minocycline Small Molecule 
Mycophenolate Small Molecule 
Penicillamine Small Molecule 
Myocrisin Small Molecule 
Abatacept Biologic 
Adalimumab Biologic 
Anakinra Biologic 
Certolizumab Biologic 
Etanercept Biologic 
Golimumab Biologic 
Infliximab Biologic 
Rituximab Biologic 
Tocilizumab Biologic 
Inflectra Bio-Similar 
Remsima Bio-Similar 
Benepali Bio-Similar 
Maball Bio-Similar 
Tofacitinib JAKs Inhibitor 
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3.3.4. Supplementary Figures 
 
Supplementary Figure 3.1: Architecture of Best Performing Longitudinal Deep Learning 
Model 
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Supplementary Figure 3.2: Sensitivity Analysis Comparing Forecasting Performance versus 
Training Size 
 
Forecasting performance increases non-linearly with the number of samples available for 
training. There is a sharp increase in performance between 50 and 100 samples. The net size of 
performance gains becomes smaller as the sample size is increased. It is important to note that 
these experiments are conducted post-hyperparameter-optimization. Therefore, they reflect the 
numbers necessary to train the optimal model but do not reflect the numbers necessary to 
identify the optimal model. 
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Chapter 4 
Predicting the Future 
 
4.1. Permissions 
Portions of this chapter was originally published in JAMA Network Open (JAMA Netw 
Open. 2019;2(3):e190606) and is available under a Creative Commons license.  
 
4.2. Forecasting Individual Rheumatoid Arthritis Patient Outcomes Using Deep Learning 
on EHR Data 
 
4.2.1. Abstract 
Importance: Knowing the future state of a patient would enable a physician to customize 
current therapeutic options to head off disease worsening, but predicting that future state requires 
sophisticated modeling and information. If artificial intelligence models were capable of 
forecasting future patient outcomes they could be used to aid clinicians and patients to 
prognosticate outcomes or simulate potential outcomes under different treatment scenarios. 
Objective: To engineer an artificial intelligence system to prognosticate the state of 
disease activity of patients with Rheumatoid Arthritis (RA) at their next clinical visit, and to 
quantify its ability.  
Design: A retrospective multi-cohort observational study ranging from Januray 2012 to 
February 2018.  
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Setting: Rheumatology clinics at two distinct health systems with different EHR 
platforms; a university hospital (UH), and a public safety net hospital (SNH). The UH and SNH 
had significantly different patient populations and treatment patterns. 
Participants: 578 patients at the university hospital and 242 patients at the safety net 
hospital met the inclusion criteria for RA, a complex systemic inflammatory disease with a 
variable course that may be difficult to predict. 
Exposure: Structured data was extracted from the Electronic Health Record (EHR) 
including exposures (medications) along with patient demographics, labs, and prior measures of 
disease activity. We developed a longitudinal deep learning method to predict disease activity for 
RA patients at their next rheumatology clinic visit and evaluated inter-hospital generalization and 
model interoperability strategies. 
Main Outcome(s) and Measure(s): Model performance was quantified using the Area 
Under the Receiver Operating Characteristic Curve (auROC). Disease activity in RA can be 
measured using a composite index score.  
Results: 578 patients at the UH were included, with a mean age of 57, 83% were female. 
At the SNH, there were 242 patients included with a mean of 60, 81% were female. Patients at 
the UH were seen more frequently (median time between visits 100 days vs 180 days at the 
SNH) and more frequently prescribed higher-class medications (biologics) (63% vs 29%). At the 
UH, the model reached an auROC of 0.912 (95% CI: [0.862, 0.960]) on a test cohort of 116 
patients. The UH-trained model had an auROC of 0.741 (95% CI: [0.649, 0.827]) in the SNH 
test cohort (n=117), despite marked differences in the patient populations. In both settings, a 
baseline prediction utilizing each patients’ most recent disease activity score had statistically 
random performance.  
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Conclusions: Building accurate models to forecast patient outcomes using EHR data in a 
complex disease is possible. Our findings suggest that these models can be shared across 
hospitals with diverse patient populations.  
 
4.2.2. Introduction 
Rheumatoid arthritis (RA) is a complex systemic inflammatory disease characterized by 
joint pain and swelling that affects approximately one in one hundred people world-wide1. A 
chronic autoimmune disease, it is associated with significant morbidity and high costs of care. 
Disease progression varies greatly between people, and while numerous treatment options exist, 
individual responses to treatment vary widely2. While advances in therapeutics and clinical 
disease management have greatly reduced the proportion of treated patients living with 
uncontrolled disease activity, remission and durable response are less common. Data from the 
American College of Rheumatology’s RISE registry indicates that 42% of patients nationwide 
had moderate or high disease activity at their most recent visit3. These data suggest that 
additional tools to facilitate and personalize disease management are needed. 
Given the volume of data available in EHRs, the number of possible patient treatment 
and outcome trajectories resulting from heterogeneous patient comorbidities, medications and 
other factors far out-number what a human, even an experienced physician, can fully utilize. 
Many machine learning methods have been applied to clinical data such as Cox Regression4, 
Random Forests5, and LASSO6. However, these are often not well-suited to forecast the future 
from EHR data, given unequal numbers of data points between patients, large amounts of 
missing data, and high variable dimensions with time-dependent interactions (Supplementary 
Table S1). Deep Learning, a sub-discipline of Artificial Intelligence, has redefined computer 
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vision7 and demonstrated multiple successes in clinical applications8 involving image data for 
melanoma9, retinopathy10, metastatic breast cancer11, and other biomedical12 and healthcare13,14 
domains. Deep Learning is being applied to a rapidly increasing number of EHR-related datasets 
(A survey of recent advances in deep learning techniques for electronic health record (EHR) 
Analysis.) and like the application of technology to any new field there are numerous 
opportunities and challenges (Opportunities and obstacles for deep learning in biology and 
medicine. Journal of The Royal Society Interface). A subfamily of deep learning called 
Recurrent Neural Networks (RNNs) have become state of the art in longitudinal predictions15, 
solving complex problems in sequence modeling fields such as language translation16 and self-
driving cars17. Longitudinal deep learning models have previously been applied to EHR data18 
(Opportunities and challenges in developing deep learning models using electronic health 
records data: a systematic review) classifying cardiovascular arrhythmias19 as well as predicting 
inpatient mortality and emergency department re-admissions20. To our knowledge, there have not 
been attempts to forecast RA disease activity for future visits using any deep or machine learning 
approach. 
Previous deep learning studies had tens of thousands of samples available for model 
training, far exceeding the number of samples that would be available for most outpatient 
conditions. To date, no study has investigated the generalizability of deep learning models using 
a smaller sample sizes typical of most complex chronic conditions cared for in the ambulatory 
setting. 
In the current work, we aimed to utilize structured data from the EHR to build a model 
that would most accurately predict future RA disease activity. If successful, the ability to forecast 
disease activity could be clinically utilized to inform the aggressiveness of treatment on an 
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individualized basis at each clinical visit. Models developed for predicting RA disease activity 
will be informative for other health conditions with quantifiable outcomes in the outpatient 
setting. 
 
4.2.3. Methods 
This study was approved by the UCSF Committee on Human Research (protocol number 
15-18282). 
 
4.2 3.1. Data Sources 
Data for this study were extracted from the EHRs of two different hospitals; a university 
rheumatology clinic, the University of California San Francisco (UH) and a safety net 
rheumatology clinic, Zuckerberg San Francisco General Hospital (SNH). UH uses an EPIC EHR 
system that contains records on approximately one million total patients and dates back to 
January 2012. The UH data for this study were accessed on July 1, 2017. SNH uses separate 
EHR vendors for inpatients and outpatients; eClinicalWorks is used for outpatients and the EHR 
contains records on 65,000 unique individuals and dates back to January 2013. SNH data for the 
study were collected on February 27, 2018. A detailed description of the methods of EHR access 
can be found in the Supplementary Methods. 
 
4.2.3.2. Definition of RA cohort 
Patients had to have (Figure 4.1): two RA-related ICD-9 diagnostic codes (any of 714.0, 
714.1, or 714.2) spaced a minimum of 30 days apart by a Rheumatologist and been prescribed at 
least one Disease Modifying Antirheumatic Drug (DMARD). These criteria have shown high 
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specificity in a recent RA cohort study (https://www.ncbi.nlm.nih.gov/pubmed/22623324). To 
further increase specificity, we required that each patient have a minimum of two Clinical 
Disease Activity Index (CDAI) scores, which are only assigned by Rheumatologists for RA 
patients at both clinics in this study. Additionally, we required patients to have one RA 
diagnostic laboratory value (either C-reactive protein [CRP] or erythrocyte sedimentation rate 
[ESR]). Together, we believe this verifies that included patients were being treated for RA at the 
clinic for a minimum of four months. Final cohort sizes that met inclusion criteria were 578 
patients at UH and 242 patients at SNH.  
 
4.2.3.3. RA Disease Outcome Metric 
The ACR endorses six different disease activity measures. The CDAI, a composite index of 
patient and physician assessments along with scoring of tender and swollen joints, is the most 
frequently used activity measure in the RISE registry and is the primary score used at both UH 
and SNH. CDAI is recorded as a raw score (0-72) but subsequently binned into four categories: 
Remission (< or =2.8), Low (2.9-10), Moderate (10-22), or High (>22) disease activity21,22 ,23. 
These four categories can then be further aggregated into a binary disease activity state, 
Controlled (Remission or Low activity, CDAI < 10) or Uncontrolled (Moderate or High activity, 
CDAI > 10). 
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Figure 4.1: Inclusion criteria and study 
design for predicting RA clinical 
outcomes using deep learning methods. 
A) Workflow and design of the current 
study. B) Clinical data manipulation of 
relevant variables for deep learning. 
Shapes refer to clinical variables that are 
contained with bins of equal lengths (i.e., 
windows). Shapes with dashed lines 
represent missing data that are set to 0. 
C) Replication cohort experimental 
design 
 
Figure 4.1: Inclusion Criteria and Study Design 
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4.2.3.4. Variables Utilized in Model 
Given the relatively small number of patients available and the complexity of time series 
models, we chose to only include variables with known clinical significance in the models. These 
variables are known to be associated with disease activity, however no study that we are aware 
of has shown them to be predictive of future disease activity. We included the following: prior 
CDAI, ESR and CRP, DMARDs (Supplementary Table S2), oral and injected glucocorticoids, 
autoantibodies (presence of rheumatoid factor [RF] and/or anti-cyclic citrullinated peptides [anti-
CCPs]), and demographics (age, sex, race/ethnicity). We chose to include only the first 
occurrence of each medication given the lack of reliable medication stop dates in the EHR. 
Considering each variable at each of four different time windows results in a reasonably large 
time-dependent total variable space of 165 total variables (29 possible DMARDs, eight possible 
Steroids, CDAI, ESR, and CRP at each time window in addition to the five static variables: 
demographics plus anti-CCPs and RF).  
 
4.2.3.5. Modeling 
Data were sorted chronologically by patient. The patient’s demographics and history of 
clinical and laboratory variables were used to predict their most recent disease activity (Figure 
4.1B). Extensive experimentation was performed to determine the optimal methods to format the 
chronological data as input and construct and train the most generalizable deep learning model 
for outpatient forecasting within this dataset. Complete information pertaining to model input, 
building, and selection are provided in the Supplemental Methods. A Transparent reporting of a 
multivariable prediction model for individual prognosis or diagnosis (TRIPOD) checklist is 
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included in the Supplement. The code to build and train the model can be found on github 
(https://github.com/beaunorgeot/deep_clinical_forecasting).  
 
4.2.3.6. Comparative Baselines  
As a first baseline, we built a classifier that uses a Bayesian prior on the likelihood of 
each outcome category (Outcome Posterior Classifier). For example, if the ratio of Controlled to 
Uncontrolled outcomes is 60:40 respectively, as in the case of the UH cohort, the model would 
assign a forecasting prediction of Controlled, 60 percent of the time. As a second baseline 
(Change Posterior Classifier), we built a classifier with two elements of prior knowledge. First 
was each individual patient’s previously recorded outcome. Second was the likelihood of 
changing outcome classes from one encounter to the next. We then built a model that considers 
each patient’s previous outcome class as well as the likelihood within the cohort to switch 
classes in order to forecast the patient’s future outcome class. For example, if the probability of 
switching outcome classes is 30 percent, the model would look at the previous outcome for each 
patient, and to forecast the patients future state, it would change the class of 30 percent of the 
patients while maintaining the class of the remaining 70 percent of the patients. 
 
4.2.3.7. Evaluation Criteria 
We chose the AUROC as our primary evaluation metric. In addition to AUROC, we 
performed sensitivity analyses in order to better evaluate the top model’s potential clinical utility. 
We assessed how often the model was confident and wrong, assuming a threshold at probability 
of Uncontrolled is equal to 0.50, and compared model performance between groups of patients 
whose CDAI score at the predicted visit was either Remission, Low, Moderate, or High Disease 
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Activity. We explored how forecasting models may be shared across institutions that may not be 
able to directly share patient data. We evaluated the impact of the number of training samples on 
the models’ performance to estimate the patient cohort size at which a hospital should decide to 
use a model trained at a different hospital, instead of building one of their own. 
 
4.2.3.8. Model Explanation and Interpretability 
We calculated Permutation Importance Score (PIS)24 to measure the contribution of each 
independent variable, including time, to the overall model performance measured by AUROC. 
We generated a graphic, which we have called a Confusion Plot, by collecting the final dense 
representation learned by the model for each patient and plotting them using T-SNE, colored by 
outcome category, to assess the coherence of the representations learned by the model. 
 
4.2.3.9. Statistical Analysis 
AUROC Confidence Intervals: AUROC confidence intervals (CI) were generated on UH 
validation cohort for model selection and for UH and SNH test cohorts for final performance 
assessment using the Delong Method (CITE ME). Models with an auROC CI spanning 0.5 are 
not statistically different from random performance. 
PIS Confidence Intervals: Variables at each time point whose PIS CI spanned the 
baseline AUROC were considered insignificant.  
 
4.2.3.10. Performance in a Distinctly Different Cohort 
We assessed three different methods of employing the model on patients from the second 
health system (SNH) (Figure 4.1C). First, we trained a model from scratch on the SNH training 
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cohort using the top-performing architecture selected via Bayesian optimization at UH. Second, 
we tested the UH model directly on the SNH test cohort. Third, we utilized model transfer-
learning and fine-tuning to update the fully trained UH model using the SNH training cohort. An 
explanation of theory of transfer-learning and fine-tuning as well as the methods that we applied 
can be found in the Supplementary Methods. 
 
4.2.4. Results 
4.2.4.1. Clinical Cohort Comparison 
The UH and SNH clinics contained substantially different patient populations based on a 
number of factors (Table 4.1). Comparatively, the UH population was larger, predominantly 
White and non-Hispanic, and seen by rheumatologists with nearly double the frequency 
compared to the population at SNH. UH patients were more than twice as likely as SNH patients 
to be prescribed higher-class medications (biologics) and were also on a broader spectrum of 
treatments. 
 
 
 
 
 
 
 
 
 
 45 
Table 4.1: Characteristics of Individuals with Rheumatoid Arthritis in the Two Health Systems 
Studied 
Population 
Characteristic 
University Clinic 
N = 578 
Safety Net Clinic 
N = 242 
Age in years, Mean ± SD 57 (15) 60 (15) 
Female, n (%) 477 (83) 195 (81) 
Race/Ethnicity, n (%) 
White 
African American 
Hispanic 
Asian 
Other 
 
296 (51) 
33 (6) 
97 (17) 
101 (17) 
51 (9) 
 
30 (12) 
19 (8) 
89 (37) 
70 (30) 
34 (13) 
EHR System Epic eClinicalWorks 
Median Number of CDAI Scores per Patient 6 4 
Median Time Between CDAI 100 days 180 days 
DMARD, n (%) 
Conventional Synthetic 
Biologic 
Tofacitinib 
 
534 (94) 
364 (63) 
29 (5) 
 
191 (79) 
70 (29) 
0 (0) 
N: Number; SD: Standard deviation; EHR: Electronic Health Record, DMARD: disease 
modifying antirheumatic drug; CDAI: clinical disease activity index. DMARD numbers reflect 
patients prescribed a DMARD at the clinic prior to their index date. Supplementary Table S2 
provides a breakdown of medications considered for each DMARD category. 
 
4.2.4.2. Primary cohort (University Clinic) results 
The best performing model was small, highly regularized, and consisted of a time-
distributed layer, followed by recurrent GRU layers and a final dense layer (Supplementary 
Figure S1). Fixed time intervals of 120 days, random sampling during training, equal 
penalization of errors for both classes, use of a combination of clinical, medication, and 
laboratory variables, and one year of each patient’s history prior to their index date provided the 
best results. The best deep learning model (Figure 4.2) demonstrated excellent forecasting 
performance (AUROC= 0.912, 95% CI [0.862, 0.960]) on the University Clinic test cohort 
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(n=116). Both baselines demonstrated near random performance: Outcome Posterior Classifier: 
AUROC = 0.535, 95% CI [0.442, 0.630]; Change Posterior Classifier: AUROC = 0.554, 95% CI 
[0.460, 0.636]). 
 
 
 
 
 
Figure 4.2: Forecasting Performance on Test 
Cohort at UH. The distribution of outcomes 
from the training cohort at UH was 60 
percent ‘Controlled’ and 40 percent 
‘Uncontrolled’ according to the Clinical 
Disease Activity Index (CDAI). This prior 
was used to train the Outcome Posterior 
Classifier at UH (Green Line, 
AUROC=0.535). The likelihood of 
switching outcomes between visits within 
the training cohort was 25 percent. This prior 
was used to train the Change Posterior 
Classifier at UH (Olive Line, 
AUROC=0.554). Deep Learning produced 
the best results (Blue Line, AUROC=0.912). 
 
Figure 4.2: Forecasting Performance on Test Cohort at UH 
 
4.2.4.3. Sensitivity and Model Explanation 
A sensitivity analysis comparing forecasting performance to the number of samples 
available for training revealed a non-linear increase in performance with linear increases in 
sample size (Supplementary Figure S2). CDAI was important for forecasting performance in 
each time window (Combined PIS=40) followed by Time itself (PIS=11). ESR and CRP 
variables contributed small but significant predictive power to the two most recent time windows 
(Combined PIS = 2,3 respectively). Steroids, as a class, at the current time window had a PIS of 
4, with Prednisone alone having a PIS of 2, but were not significant in other windows. Multiple 
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DMARDs were significant but with PIS less than two. The model was confident (probability 
greater than 0.8 or less than 0.2) and incorrect only two times out of the 116 test samples, or 
1.5% of the time. These errors occurred for patients whose future visit CDAI score fell on the 
threshold between the outcome classes (CDAI =10) +/- 2. Performance was equal for patients 
whose future CDAI was clinically determined as either Remission, Low Activity, or High 
Activity. Predictive performance was lowest for patients whose future disease activity was 
Moderate; most of the incorrectly classified patients in this group had CDAI scores near the 
classification threshold (CDAI in the range of 10-14). The Confusion Plot (Figure 4.3) appears as 
a nearly one-dimensional manifold (a curve). Instead of dichotomous clusters for each outcome 
category, the model learned a continuous representation of the patients. Distinct decision 
boundaries based on the Confusion Plot can be seen. 
 
 
 
 
 
Figure 4.3: Confusion Plot consisting of 
the final embedding of the model, the 
Learned Patient Trajectory Vectors, 
visualized using t-SNE, colored by the 
ground truth of the patients outcome at 
their next visit. Yellow for uncontrolled . 
The model places observations onto a one-
dimension manifold with Controlled and 
Uncontrolled outcomes clustering along 
different ends of the manifold. 
 
Figure 4.3: Confusion Plot, Learned Patient Trajectory Vectors 
 
 
 48 
4.2.4.4. Safety Net Cohort Results 
When the top-performing model architecture was trained from scratch on the Safety Net 
Clinic training cohort (Figure 4.4; n=125) it produced reasonable results (AUROC=0.623, 95% 
CI [0.522, 0.724]) on the Safety Net Clinic test cohort (n=117). Employing a model that was 
trained on all the UH patients (n=578) directly on the Safety Net Clinic test cohort dramatically 
increased forecasting performance (AUROC=0.741, 95% CI [0.649, 0.827]). Utilizing transfer-
learning and fine-tuning to update the UH-trained model using the Safety Net Clinic training 
cohort did not provide any additional improvements in performance (AUROC = 0.739). Both 
baselines demonstrated random performance: Outcome Posterior: AUROC = 0.507, 95% CI 
[0.391 - 0.615]; Change Posterior Classifier: AUROC = 0.544, 95% CI [0.460 - 0.622]).  
 
 
 
 
Figure 4.4: Safety Net Cohort Results. 
The distribution of outcomes from the 
training cohort at ZSFG was 50 percent 
‘Controlled’ and 50 percent 
‘Uncontrolled’. This prior was used to 
train the Outcome Posterior Classifier at 
ZSFG (Green Line, AUROC=0.507). 
The likelihood of switching outcomes 
between visits within the training cohort 
was 25 percent. This prior was used to 
train the Change Posterior Classifier at 
ZSFG (Olive Line, AUROC=0.544). 
Training the deep learning model 
exclusively on the ZSFG train cohort 
produced an AUROC that was 
substantially better than random (Purple 
Line, AUROC = 0.623). Training the 
deep learning model on the larger UH 
patient cohort produced the best overall 
results test cohort (Blue Line, AUROC 
=0.741) 
  
Figure 4.4: Forecasting Performance on Test Cohort at SNH 
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4.2.5. Discussion 
4.2.5.1. Main Findings 
In this study, we used deep learning to forecast future RA disease activity scores across 
two health systems and compared those results to prediction models that only used a patient’s 
most recent CDAI. Contrary to our expectations, a patient’s most recent CDAI alone was 
actually a very poor predictor of their index CDAI, as evidenced by the statistically random 
results of both Baselines. The history of disease activity, lab values, and medications all together 
were required to create the strongest predictor of the disease activity at the next visit. Just over 
20 variables were found to be significantly important for predictive accuracy, a relatively small 
number, however these variables have time-dependent interactions which adds considerable 
complexity. For example, the best deep learning model substantially outperformed the Multilayer 
Perceptron (which acted as a surrogate for Logistic Regression) (Supplemental Results Table 1) 
demonstrating the utility of more complex DL models for this task. 
Our results show that deep learning models can be trained on cohorts of only a few 
hundred patients to accurately forecast RA patient outcomes using EHR data. We also found that 
our model performed well when applied to a second health system with a distinct 
sociodemographic population and separate EHR system. Given the many differences in the 
demographics and social determinants between the patients in these centers, the ability of the 
model to function significantly above random is highly promising. By considering no more than 
the most recent year of each patient’s history but allowing patients to have as little as four 
months of history, the model could have utility for patients at all stages of their care. While the 
amount of data that a rheumatologist must synthesize in one visit in order to make decisions is 
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large and growing, the results presented here indicate that use of artificial intelligence models to 
assist with this in the near future is promising. 
 
4.2.5.2. Prior Work 
Early successes in the application of deep learning to clinical forecasting19,20 ,25 
demonstrated that longitudinal deep learning models outperformed traditional machine learning 
approaches and that reasonable predictive performance was possible. However, these studies 
were limited in their clinical utility by the inclusion of patients without clinical risk indicators for 
the outcomes being predicted, the sheer numbers of patients used for training, and a lack of 
evaluation of model performance across hospitals with diverse patient populations. This work 
addresses these open questions by focusing on a clinically relevant patient population and 
outcome at both a large university hospital and an associated safety-net clinic. The model trained 
on the larger UH population produced the best results on the SNH population, demonstrating the 
power of larger training sizes and the interoperability of models between hospitals with diverse 
patient populations. While it is perhaps discouraging that utilization of transfer-learning and fine-
tuning methods to update the fully trained UH model using the SNH training cohort did not 
provide any additional improvements in performance, we suspect that this is due to the fact that 
the SNH training cohort was probably too small and thus suffered from over-fitting. 
 
4.2.5.3. Limitations 
With data from two distinct hospital systems and just over 800 total patients, inferences 
about large scale generalizations cannot be made. Accordingly, this work is limited to being a 
promising proof-of-concept. There are numerous inherent biases in medicine, perhaps most 
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notably are those relating to sicker patients generally having a great number of data points. We 
sought to address this bias at multiple levels. Most notably, by giving all patients the same 
number of time windows and setting that to be equal to the smallest median number of visits in 
either cohort (Table 4.1) and then by dropping all but the most recent values within each window 
for a patient. Additionally, including fewer variables in the model lessens the risk of spurious 
associations between variables. However, the potential for theses biases runs deep. For example, 
physicians may choose to order or not order labs for a given patient at a given time point based 
on factors that are not modeled here, including physician preference. Similarly, some physician-
patient combinations may be more or less likely to switch a patient’s treatment strategy. 
Intimately tied to these challenges is the decision about what to do when the value of a patient’s 
variable is missing from a time window. Our choice to replace missing continuous variables with 
a value never observed in our data set (zero) is not perfect, as the replaced value more closely 
resembles healthy patients than sick ones, but it does seem to be the replacement option that is 
least likely to reinforce this bias. Statistical imputation or forward filling are likely to introduce 
or reinforce bias for a health condition that varies so much between individuals and within a 
person over time and where most patients’ disease activity is uncontrolled. While we strove to 
reduce biases in our data and modeling, we cannot fully eliminate them. Using the treating 
physician as variable to model, while not possible with this current study, could potentially 
reduce bias further in the future. To the best of our knowledge, there are no clinical methods for 
explicitly forecasting individual patient disease activity states at future visits nor has any 
methodology for this ever been employed in a clinic. While this underscores the need for the 
work introduced in this study, it leaves us without any clinical baseline to compare machine 
learning results to.  
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Finally, the performance of the UH-trained model on the SNH test cohort 
(AUROC=0.741) is too low to be of immediate clinical utility, however the performance is 
evidence that the model learned something robust and transferable. Given the notable differences 
in the two clinical populations, a method of exploring whether the differences in model 
performance between the populations was due exclusively to the differences in the treatment 
populations would have added clarity to the study. However, while the patient populations are 
different in many ways that we can measure (Table 4.1), we know that they are also different in 
many ways that we cannot reliably measure (other socioeconomic factors, environment, social 
structure, insurance coverage, and more) making an actual patient matching algorithm 
impossible given the relatively small sizes of both populations. For complex chronic diseases 
like RA, patient populations that number in the hundreds are unlikely to capture enough clinical 
or social variation to adequately represent the complete disease spectrum. Our sensitivity 
analysis revealed that increasing the training set size lead to non-linear increases model 
performance. Thus, adding EHR data from other institutions seems likely to result in additional 
gains in predictive power as well as insights into the subtler factors responsible for the model’s 
performance. 
 
4.2.5.4. Summary and Implications 
The future decision support that we envision will involve aggregating data from multiple 
institutions, training the model on all of that data, and then deploying the model in small clinics 
as well as large hospital systems giving everyone access to the most robust models trained on 
largest and most diverse patient populations possible. Using such a forecasting model will help 
clinicians and patients understand predicted disease trajectories. This in turn, will help inform the 
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aggressiveness of treatment. We find that there are many clinical situations where there is 
equipoise about whether and how to augment therapy for RA. Patients may have been stable for 
some time, but come to the current visit with a CDAI score just over the threshold of moderate 
disease activity. Alternately, they may have been in moderate disease activity over several visits 
and have been experiencing adverse effects related to their current DMARD regimen. In 
situations like these, where waiting until the next visit to consider any medication changes seems 
like a reasonable option, having a prediction from the algorithm that indicates that the CDAI 
score at the next visit will likely be worse may push a provider and patient to action. These 
situations "at the margin" are the ones that are most likely to benefit from the algorithm. Given 
the algorithm’s already strong performance at identifying patients that will have controlled 
disease activity at their next visit, probability thresholds could be analyzed to specifically 
improve outcomes for these patients “at the margin”. As a patient’s health status and other 
variables change, the model will adapt its predictions, allowing both patients and clinicians to 
use this information to inform treatment changes dynamically. As we move toward personalized 
medicine, such models can be used to simulate trajectories given different treatment scenarios. 
The addition of molecular, genomic, and other types of data to EHR data to generate treatment 
response trajectories would allow a more personalized medicine approach to RA care. 
With large national registries, such as the American College of Rheumatology’s RISE 
registry, now available for rheumatic and other diseases, we see a rich future in the application of 
deep learning to longitudinal patient care. Model performance is nearing the point where they are 
good enough to warrant launching a prospective clinical trial to evaluate their usefulness in 
aiding clinicians and patients to prognosticate RA outcomes or simulate outcome trajectories 
under different treatment scenarios.  
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4.2.6. Conclusion 
In the current study, we built an accurate longitudinal deep learning model to forecast 
patient outcomes in two distinctly different rheumatoid arthritis populations that numbered in the 
hundreds, much smaller than what once believed to be necessary for DL. These models can be 
shared across hospitals with different EHR systems and diverse patient populations. In the future, 
models built from large pooled patient populations are likely to be the most accurate, giving 
everyone access to the most robust models trained on largest and most diverse patient 
populations possible. The methods used to develop models for predicting RA disease activity 
will be informative for other health conditions with quantifiable outcomes. 
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Chapter 5 
MI_CLAIM 
 
5.1. Minimum Information about Clinical Artificial Intelligence Modeling 
5.1.1. Abstract 
Artificial Intelligence (AI) models have become widely used tools for the generation of 
clinical insights, prognostics, diagnostics, and classification. Although many significant results 
have been derived from clinical AI studies, one limitation has been the lack of standards for 
presenting and exchanging the results from such models. Here we present a proposal, the 
Minimum information for Clinical Artificial Intelligence (MI_CLAIM), that describes the 
minimum information required to ensure that the performance of clinical AI models can be easily 
interpreted and that results derived from model analysis can be independently verified in similar 
settings. The ultimate goal of this work is to establish a standard for designing, recording and 
reporting AI-based clinical informatics studies, which will in turn facilitate transparency and the 
establishment of trust and ultimately enable the utilization of such models in the clinical setting.  
With respect to MI_CLAIM, we concentrate on defining the content and structure of the 
necessary information rather than the technical format for capturing it. 
 
5.1.2. General Principles of the Claim Design 
As a starting point, we propose that for the results from clinical AI models to have the 
most value, they should satisfy the following requirements: (i) the recorded information about 
each study should be sufficient to interpret the clinical utility of the results and should be detailed 
enough to enable comparisons to similar studies and permit replication in similar settings and (ii) 
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the code to build, train, and evaluate an identical model (including examples of expected input 
data formats) should be openly provided to enable external validation and utilization of 
successful models (See Table 5.1). The Figure 5.1 further shows the interconnection of these 
parts/components of clinical AI study. 
 
Figure 5.1: The (Six) Parts of MI_CLAIM - A Schematic Representation of the 6 Components 
of a Clinical AI Study 
 
The first requirement recognizes that overfitting is a primary concern when dealing with 
flexible models and clinical data, while transparency about the distribution of clinical variables 
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and demographics present in the model building and testing cohorts is essential to properly 
assess fairness/bias for all groups and the overall clinical utility.  
The second requirement addresses the truth that sharing clinical data often is neither 
possible due to institutional patient privacy policies, nor would it be advisable to share even at 
institutions without such safeguards in place. Clinical data is much more sensitive than other 
data, such as microarray data, and should only be handled by people with proper training (which 
is currently decided at the institution level). In any case, the validation of the exact results is 
generally of less interest than whether or not the results validate in a new cohort of patients, 
which researchers at different institutions can do with their own data using security features 
determined by their institution. Therefore in the space of clinical AI models, the limiting factor 
for validation is not the raw data itself but replication of the exact model building pipeline 
(including any feature engineering or transformations). The code for complete pipelines, 
beginning with a few examples of the raw input data (in it’s proper format, but populated with 
random numbers) and ending w/ performance evaluation should be provided as well-documented 
scripts or notebooks, including exact environment requirements, such that a new researcher can 
run the pipeline end to end, without any modifications necessary to the code. This provides the 
new researcher with everything necessary to rapidly validate the results in their own cohorts and 
will additionally facilitate the transfer of pipelines across clinical use-cases.  
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Table 5.1: The (Six) Parts of MI_CLAIM - A Schematic Representation of the 6 Components of 
a Clinical AI Study 
Part/Component 
of Clinical AI 
Study 
Description 
Part 1: 
Experimental 
Design  
 
This section describes the study as a whole. Normally, this can be broken down into four 
subsections: The clinical setting, performance measures, population composition, and 
baselines. (a) The clinical problem and the workflow in which a successful model would be 
employed, and in what ways, if any, the experimental design in which the model will be 
trained and tested differ from that (including the acquisition of data). (b) The Performance 
Measurements that will be used to evaluate the results and how do those measurements 
would translate to successes and failures in the clinical setting. (c) The composition or 
makeup of the population available for training and testing and how representative that 
sample is of a real-world populations for the clinical question at hand. Additionally, 
whether performance among certain sub-groups of the population is important or if 
aggregate performance statistics across the population is all that matters. (d) Are there any 
current solutions employed in the clinic that can act as baselines? 
 
Part 2: 
Establishment of 
Out of sample 
validation 
 
This section is tightly coupled to Section 3 and builds upon the Experimental Design by 
detailing the steps that will be taken to prevent information leakage, overfitting, 
generalization out of sample, and therefore a meaningful interpretation of the study results. 
Of paramount importance is the splitting of all available samples into two groups at the 
very beginning of the study, one for development and an independent test cohort. Truly 
appreciating the importance of this simple task requires an intuitive understanding of three 
fundamental statistical concepts: populations, samples, and parameters (aka: measurements, 
features, variables). To briefly discuss these concepts, let's imagine that we're talking about 
type 2 diabetes. In truth the Population is the total of all patients anywhere w/T2D. This is 
the population that we'd really like to learn about. But since we don't have access to all of 
the them, we have to use all the people/patients that we do have access to as a surrogate for 
the true population. But it is crucial that we always keep in mind that our 'population' is not 
the true Population. All of our best practices are set up to maximize the inferences that we 
can draw about the true population using our surrogate population. Samples are the groups 
of individual people that we draw from our surrogate population. The most common 
sample types that we talk about in machine learning are training, validation, and testing 
cohorts. Cross-validated splits are also examples of samples drawn from our (surrogate) 
population. In any given sample there is an exact correlation between independent variables 
and the dependent variable(s). But that correlation tells you absolutely nothing about the 
TRUE-ASSOCIATION between variables and outcomes in the TRUE POPULATION. 
Parameters (also known as Features or variables) are things that you have measured about 
each of the people in your sample or population. For example: height, medications 
prescribed, BMI, or eye color. If you build models or conduct statistical tests on the entirety 
of your surrogate population (all the data you have), you will have turned your 'population' 
into a sample and YOU WILL LOSE ANY AND ALL ABILITY TO MAKE ANY 
CLAIM AT ALL about how your model performs in the population that you care about or 
the predictive importance or association of your variables and the outcome. You instantly 
move from predictive to descriptive statistics. 
 
Members of the test cohort should reflect the population and distribution of the clinical 
outcomes of interest. We recommend stratified sampling where possible, and reporting a 
comparison of statistics describing the distribution of variables and outcomes within 
training and testing populations otherwise. The development cohort may be used in any 
manner that facilitates data engineering and model selection. The two most common 
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Part/Component 
of Clinical AI 
Study 
Description 
approaches are either cross-validation, which is typically used for smaller datasets, or sub-
dividing the development cohort into training and internal validation set for large sample 
sizes. Under no circumstances can cross-validation be used as a replacement for an 
independent test cohort. Validation at a separate clinic or hospital system is necessary to 
make any claims about generalization. 
 
Part 3: Data 
Engineering and 
Model Selection 
 
With an independent test set established, the development cohort can now safely be used to 
estimate the best (a) format of data and (b) type of model to solve the clinical problem. For 
all studies this section should begin with data providence, clearly specifying where the data 
in its most raw form came from and how it was formatted. It should then (a) describe any 
transformations that were done to the data prior it being fed into the model as input. For 
traditional machine learning studies, these transformations will typically be feature 
engineering, for deep learning models this frequently involves the normalization of 
continuous variables and one-hot, or integer, encoding of categorical variables. Next, the 
section should describe the type of models that were evaluated and how a top performing 
combination of model and data formatting will be selected. Typically these two elements of 
optimal data format and model are highly interdependent and therefore the process to arrive 
at the best combination is often iterative. An example statement might look like: “5-fold 
cross-validation on the development cohort was used to evaluate the results of a grid search 
comparing number of input features, number of variables to consider at each split, number 
of splits, and number of trees for random forest models. No other model types were 
considered. The top performing approach was selected on the basis of median AUC.” This 
section should also describe the process preparing the baseline methods for use, if any were 
available. 
 
Part 4: Out of 
Sample 
Evaluation 
 
With the optimal model selected and comparative baselines tuned from Section 3 it is time 
to evaluate them once, and only once, against the test cohort. This section will include a 
typical results table with the performance of the baselines and models tested along with 
appropriate statistics for significance. If any important sub-groups of patients were 
identified in Section 1, performance of the baseline and model in each of those subgroups 
should also be provided in an identically formatted table. 
 
Part 5: Model 
Explanation/Inte
rpretation 
 
Having some intuition of how complex models are behaving is relevant to most clinical 
problems and typically serves one, or more of three purposes. First, it may provide a sanity 
check that the model reached its accuracy by focus on relevant inputs and not unanticipated 
artifacts of the data. Second, it can uncover bias which model users should be aware of. 
This bias could relate to fairness or anticipated points of failure. Third, there are many 
potential tasks that clinical AI models might be applied to that no human is definitively 
capable of performing well. In these cases, it may be useful to harness what the model has 
learned to generate testable hypotheses to move those fields forward.  
 
We agree with Spiegelhalter that useful explanations should contain at least two elements; 
Global explanations consisting of what the model learned overall about the relationship 
between the independent and dependent variables, and local explanations, consisting of 
why the predictions for specific cases were arrived at. 
 
SHAPs and MAgEC provide two alternative approaches for both the global and local 
examination and interpretation of most models. 
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Part/Component 
of Clinical AI 
Study 
Description 
 
If no explanation methods are available important insights into model behavior can still be 
gleaned by a more detailed examination of its performance. For classification models a 
description of the top-5 cases where the model was most confident and correct, most 
confident and incorrect, and least confident is a good starting point. The same philosophy 
can be applied to regression models by examining the cases where the model had the 
largest error above the true answer, the largest error below the true answer, and the number 
of times it predicted the median value. 
 
Part 6: 
Reproducible 
Pipeline 
 
The code for complete pipelines, beginning with a few examples of the raw input data (in 
its proper format, but populated with random numbers) and ending w/ performance 
evaluation should be provided as well-documented scripts or notebooks, including exact 
environment requirements, such that a new researcher can run the pipeline end to end, 
without any modifications necessary to the code. This provides the new researcher with 
everything necessary to rapidly validate the results in their own cohorts and will 
additionally facilitate the transfer of pipelines across clinical use-cases. The goal here is not 
for a new researcher to replicate the results but the exact process by which the results were 
generated. This enables the new researcher to determine whether the results validate in their 
own clinical settings and facilitates the transfer of pipelines from one clinical task to 
another rapidly speeding up prototyping and helping the entire field to develop best 
practices. 
 
 
5.1.3. Discussion 
My goal is to develop a standard that can serve both clinical scientists and data scientists. 
To that end, I hope that this description will stimulate discussion of the proposed MI_CLIAM 
standards and I encourage the clinical community, as well as the AI community, to provide me 
with their views on how this standard can be improved. For this purpose an e-mail discussion 
group has been set up with the release of this manuscript as an independent document outside of 
my dissertation. 
 
 
  
 65 
Chapter 6 
MAgEC 
 
6.1. Understanding and Leveraging Complex Models: Framework for understanding, 
explaining, and comparing clinical AI models 
 
6.1.1. Introduction 
In medicine, and indeed in many other fields, the information needed to understand and 
intelligently act within the overall landscape is comprised of 3 overlapping hierarchies of 
understanding: Cases, or what variables/factors about a specific individual contribute to or drive 
their outcome; Features, or the average effect of each variable across many cases; and 
Populations, patterns in cases that allows them to be logically grouped together. Therefore, any 
attempt to examine and understand a model in these types of settings must address what the 
model has learned in regards to each of these hierarchical elements of information. However, 
historically methods for examining models have generally addressed only one or at most two 
elements in the hierarchy which has lead to an incomplete understanding of the models which 
has lead to an inability to adequately assess true model performance including examining it for 
bias and anticipating it’s performance in future uses; as well as an ability to completely leverage 
what models have to learned to generate new knowledge in imperfectly understood fields such as 
medicine.  
 Further, many methods for understanding models has been model-specific which has 
lead to two deep challenges;:first it has made model builders make decisions for trading off the 
model types that they would like to employ to best solve the current problem with the types of 
 66 
methods that they would like to use examine what the model has learned and potentially explain 
it to other stakeholders; second, it has made it difficult/impossible to objectively compare what 
multiple different types of models trained to do the same task have learned. Since there has not 
been a direct way of comparing what different types of models have learned about the same data 
and task, this has lead to an often unaddressed and insidious oversight in the field which is 
confusing what a specific model has learned about the association of input and response 
variables with some underlying truth about the nature of the actual association between the 
inputs and the responses.  
There are two broad reasons that understanding what a model has learned is important. In 
some areas, the task for which a model is trained for is well understood (such as 
radiology/pathology/lending) in which case models should be examined in order to verify that 
they are indeed focusing on plausibly causal variables and not artifacts and that they are 
behaving fairly and ethically. In other areas (such as forecasting outcomes or selecting optimal 
treatment strategies in complex disease) it may be that no human is definitively capable of 
performing the task for which the model is being trained, in which case it is critical to harness 
what the model has learned to generate testable hypotheses to move those fields forward (and the 
model examination tasks discussed prior become more of a sanity check in these less understood 
tasks).  
Here we present a unifying framework for understanding and explaining clinical AI 
models that address the above desiderata and additionally provide a method to implement it. We 
present these through two relevant examples; a well understood task using the public Pima 
Indians Diabetes Dataset, and a very new task of using longitudinal model to forecast future 
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outcomes for patients with Rheumatoid Arthritis. Source code, Jupyter Notebooks, and data (for 
one of the tasks) are made available.  
 
6.1.2. Methods 
6.1.2.1. Goal 
To develop a simple and intuitive method for explaining models of arbitrary complexity 
to an audience that are not experts with the inner workings of gradient-based models. The 
method must and be able to generate local and global explanations in a unified manner.  
 
6.1.2.2. MAgEC 
Conceptually, what our method does is to linearize a model around a given feature and 
time point (if using a longitudinal model). This is intuitive. Complex functions often behave 
linearly in the very near vicinity of a given point. This can be thought of as a local partial 
derivative.  
Each patient can be represented with a two dimensional table, where each row is a 
variable and each column is a time point. Each cell in the table is the value for each variable at 
each time point.  
The first step in the method is to calculate the predicted outcome for each case(patient) 
using the original/observed data. The predicted outcome is either a probability for classification 
tasks or a real number for regression tasks. The next step is to iteratively alter the value for each 
cell in each patient’s table, while maintaining the original data values for all other cells, run each 
patient with the updated cell value through the model, and calculate how that single alteration 
affects the predicted outcome. For example, in a binary classification task, a particular 
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case/patient ‘A’ may have a predicted probability of having outcome == 1 as .68 using the 
original data. After perturbing a single variable,X, and re-running the patient-A through the 
model, we might observe that the patient-A’s probability of outcome==1 has changed from .68 
to .72. To compare the effect of variable X on the outcome, for patient-A, we take the difference 
of the logits between the observed data and the perturbed data. The result then (the difference of 
logits: new_logit - baseline_logit) can be interpreted identically to the coefficient in a linear or 
logistic regression model (the constant/linear effect of X on the outcome). Indeed, we show that 
in the case of a regression model, DECs exactly recover the variable coefficients when applied to 
the mean of the sum of the individual cases for each variable/timepoint.  
The nature of the perturbation within a cell is determined by the original data type of the 
variable, continuous or categorical. Continuous variables are perturbed by increasing their value 
by a marginal amount, such as 1e-3, which represents the logit for that variable as the limit goes 
to zero. This can be described as the change in the predicted outcome with a nearly zero increase 
in the given variable. The amount of the change is technically a hyperparameter of the method, 
which we refer to as epsilon by convention, however our initial experiments have shown the 
method results to be extremely robust to changes in epsilon (see supplement) and we currently 
leave it as a fixed parameter. Categorical variables are assumed to be one-hot encoded. The state 
of categorical variable is altered by switching the encoding from 0 to 1 if the original state was a 
0, and vice-versa if the original state was a 1. Categorical variables with more than two levels are 
treated cohesively. For example, each level is altered iteratively, one at a time, within the 
category to ensure that invalid combinations of variables do not occur.  
We then apply the process for each cell in each case/patient’s two-dimensional 
representation table. Therefore, this method takes in a two-dimensional table for each case where 
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the cell values are the feature values and it outputs a two-dimensional table for each case where 
the cell values are the differences between the logit generated by the original feature and the logit 
generated by the perturbed data.  
 
6.1.2.3. Cases 
To understand what the model has learned about how changes in each variable will affect 
the outcome for individual cases (case heatmaps) this is the end of the technical process all that 
remains is interpretation of the results. For a given case, if a given feature was present in their 
original input data, and the logit for that feature is positive and the case’s actual outcome was 
positive, then model attributes a portion of the case’s improvement to that feature. If a given 
feature was not present in the original input data for a case, then the logit represents the model’s 
prediction of the change in the case’s outcome if that feature was added. ((Probably belongs in 
Discussion: Care should be taken to ensure a realistic interpretation of these results in each 
situation. In particular, in medicine it may be important to bin your model’s variables into 
categories of potentially actionable/testable (such as treatment choices) and non-actionable (such 
as diagnoses, vitals, demographics). While this method may provide an implicit treatment 
recommendation, for example in the form of a predicted response to each possible treatment 
option, these recommendations should be considered for research purposes only and not for 
actual clinical care. The recommendation comes from the explanation, which is developed from 
what the model has learned. Not only is it likely that a given model is imperfect from a 
prediction perspective, and indeed all explanations should be interpreted in the context of a 
model’s overall ability to perform the task for which it was trained, but model’s are also subject 
to the same sampling bias that physicians are. Controlled, real-world, trials will be necessary to 
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validate any insights or promising approaches discovered through model 
explanation/examination. )) 
 
6.1.2.4. Features 
To understand what the model has learned about the ‘big picture’ of how a particular 
variable influences the outcome, on average, a coefficient for each feature (at each timepoint) 
can be generated by calculating the mean of the logits for all of the individual cases for that 
feature/timepoint. We call these Directional Effect Coefficients (DECs). As with logistic 
regression, DECs are a linearization of the outcome to the input feature and (keep the following 
here, or put it with Cases??),they provide the constant association between the feature and the 
outcome, and can be interpreted as the model’s (average) sensitivity to the input feature for each 
patient. 
 
6.1.2.5. Population 
Populations are defined on the basis of similarity or distance. For example, similarity 
could mean living in a similar region or it could mean having traits in common. To identify 
populations or subgroups, one must first define what measure of similarity they will use for 
comparison. For me, an appealing metric of similarity in the clinical setting is the association 
between independent variables and dependent variables, or the effect of an input variable on the 
patients outcome. Applying this metric we can say that two patients are similar with regards 
Variablei if, while accounting for all other variables, a similar change in Variablei for both 
patients results in a similar change in their clinical outcome. For example, if the outcome of 
interested in is hA1C at their next visit, two patients may be considered similar with respect to 
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BMI if, while accounting for all other variables such as medications and demographics, changing 
each person’s BMI by a set amount results in a nearly identical change in their hA1C at the next 
visit. In addition to providing a convenient measure of similarity between patients, this approach 
could also serve as a method for treatment recommendation. If we can identify patients that have 
similar responses to a particular drug, while accounting for all of their other variables, we could 
use that to select an optimal treatment for them. Using MAgEC, this similarity score can be 
generated by simply plotting coefficients against patients, ordered by coefficient magnitude, to 
identify those patients who are most similar. 
 
6.1.2.6. Datasets 
(1) The Boston Housing Dataset was used to generate a linear regression model to which 
MAgEC was applied to. The coefficients from the model itself were compared to the MAgEC 
coefficients to assess the fidelity of MAgEC coefficients in a purely linear model.  
(2) The Pima are a group of Native Americans living in Arizona. A genetic predisposition 
allowed this group to survive normally to a diet poor of carbohydrates for years. In the recent 
years, because of a sudden shift from traditional agricultural crops to processed foods, together 
with a decline in physical activity, made them develop the highest prevalence of type 2 diabetes. 
For this reason they have been subject of many studies. 
The dataset includes data from 768 women with 8 medical diagnostic predictor variables 
and one target variable, Outcome 
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Variables: 
• Number of times pregnant 
• Plasma glucose concentration a 2 hours in an oral glucose tolerance test 
• Diastolic blood pressure (mm Hg) 
• Triceps skin fold thickness (mm) 
• 2-Hour serum insulin (mu U/ml) 
• Body mass index (weight in kg/(height in m)^2) 
• Diabetes pedigree function (see the paper) 
• Age (years) 
• The last column of the dataset indicates if the person was diagnosed with diabetes within 
5 years (1) or not (0) 
 
Source: The diabetes data containing information about PIMA Indian females, near 
Phoenix, Arizona has been under continuous study since 1965 due to the high incidence rate of 
Diabetes in PIMA females. The dataset was originally published by the National Institute of 
Diabetes and Digestive and Kidney Diseases, consisting of diagnostic measurements pertaining 
to females of age greater than 20.(Smith et al, 1988) 
 
(3) Data and Model from Assessment of a Deep Learning Model Based on Electronic 
Health Record Data to Forecast Clinical Outcomes in Patients With Rheumatoid Arthritis 
(Norgeot et al, 2019) 
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6.1.3. Results 
MAgEC coefficients perfectly match regression coefficients on linear models (Table 6.1). 
All three models that were developed to fit the Pima Indians dataset (logistic regression, random 
forest, MLP) achieved comparable results on the test set (~79%, See Table 6.2) which is 
consistent with published results. Interestingly, when compared on the basis of coefficients, 
either regression or MAgEC, the models learned different magnitudes of effect for the variables 
and sometimes different directions of effect (Figure 6.1: MLP MagECs vs Logistic Regression 
Coefficients).  
 
Table 6.1: Boston Housing Data: Comparison of MAgEC to Regression Coefficients in Linear 
Model - Direction of Effect Coefficients 
Our Method  
Actual Linear Coefficients 
from Linear Regression 
Model 
 0   Coefficients 
features   features  
NOX -17.795759  NOX -17.795759 
DIS -1.475759  DIS -1.475759 
PTRATIO -0.953464  PTRATIO -0.953464 
LSTAT -0.525467  LSTAT -0.525467 
CRIM -0.107171  CRIM -0.107171 
TAX -0.012329  TAX -0.012329 
AGE 0.000751  AGE 0.000751 
B 0.009393  B 0.009393 
INDUS 0.020860  INDUS 0.020860 
ZN 0.046395  ZN 0.046395 
RAD 0.305655  RAD 0.305655 
CHAS 2.688561  CHAS 2.688561 
RM 3.804752  RM 3.804752 
Note: Boston Housing Data 
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Table 6.2: PIMA Results - PIMA Model Performance 
Model Accuracy AUC 
Logistic Regression 78.6  
Random Forest 79.2  
MLP 79.2  
  
 
Figure 6.1: MLP MagECs vs Logistic Regression Coefficients - Comparison of MLP MagEC 
Distribution and Logistic Regression coefficients directly from the model.  
 
Box and Whisker plot (and all black dots) show the distribution of MAgEC coefficients for each case within the test 
set. Red dots represent the logistic coefficients learned by the logistic regression model.  
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Figure 6.2: PIMA MagECs from MLP for a single patient  
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Similar patients: changes in bloodpressure expected to have similar changes in the probability of 
developing diabetes within 5 years, given all other variables  
 
 
Figure 6.3: MagEC Clustering of PIMA patients on BloodPressure 
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Figure 6.4: RA Results - Feature-Level RA MagEC 
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Figure 6.5: Individual RA Case MagEC 
 
 ** Table showing case number (randomized), case outcome, MagEC, and variables that were 
actually present for that case.  
 
6.1.4. Discussion 
6.1.4.1. Summary 
MAgEC provides an intuitive explanation of arbitrarily complex models for anyone that 
is familiar with regression coefficients. It provides explanations on both the global and local 
levels and also adds in a population level (or similarity between cases) explanation. While it is 
perhaps most useful in the context of deep learning, MAgEC can also be used to extend utility of 
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Random Forests and SVMs and allowing what many different model types have been learned to 
be compared directly. When MAgECs are visualized as a heatmap for temporal models they 
make it possible to understand complex temporal trends from a single image.  
 
6.1.4.2. Comparison to Prior Work 
SHAPs and LIME are existing methods in this space. LIME functions by generating 
surrogate data for a particular patient and then fitting a linear model to the surrogate data to 
generate an explanation. As such, it is currently limited to generating local explanations only. 
LIME is known to be highly sensitive to its methodological hyperparameters. I hve found it to 
generate non-sensical results on the data for this study, assigning direction and magnitudes of 
effect that did not align with classification labels. This was verified independently by a 
collaborator.  
SHAPs functions by comparing gradient changes between cases and some background, 
essentially yielding how the current case differs from the average case with respect to each 
variable. I found this method well implemented and the results to be logically consistent. While 
it does not currently support global explanations, it could be directly extended to do so. SHAPs, 
while flexible is not truly model agnostic, it only supports models that learn via gradient descent. 
As such, it is not possible to compare deep learning models to random forests or regression 
models, two models that are highly utilized in clinical research, to determine if what they have 
learned is similar or divergent. A greater challenge of the SHAPs method is the explanation 
method itself, explaining complex models using gradients is simply not intuitive for most non-
ML experts. Thus it may not facilitate trust and transparency to non-expert audiences. We 
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consider MagEC an alternative, not an improvement over SHAPs, useful for a different set of 
practitioners and potentially a different set of problems.  
Both SHAPs and LIME have demonstrated utility in images data and NLP, in addition to 
tabular data. At the moment MAgEC only supports tabular data.  
 
6.1.4.3. Limitations 
Currently there is no mathematically rigorous way to set epsilon, the unit of change, for 
continuous variables. Different values of epsilon have been shown to generate slight changes in 
the MAgECs. This is intuitive and its relevance is unclear. Choosing a value between 1e-3 and 
1e-6 produces reasonably stable results in practice.  
MAgEC has been designed initially for clinical models, which have traditionally used 
exclusively tabular data. At the moment MAgEC has no application extensions for images or 
NLP. Extensions for NLP models are fairly straightforward and are planned. Image extensions 
are not currently on the roadmap, I feel like SHAPs does an excellent job in that space already 
and there is no need for an alternative.  
 
6.1.4.4. Future Directions 
Predicted ‘best treatments’ can be assigned by generating MAgECs for a patient, 
extracting only the coefficients for potential treatment options and ranking them in ascending 
order. The highest rank is presumably the best option. This assertion could be strengthened for 
each patient by identifying prior patients who actually got that drug and had similar coefficients 
for that drug and checking their outcomes.  
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An approach to setting epsilon, either as one exact number or calibrating it for each 
model, should be explored. 
Currently, MAgECs provide direction and magnitude of effect for single variables while 
accounting for all other variables. Ideally, coefficients or something equivalent to directly 
describe interactions (like a DEC for age*preg*glucose that is LEARNED not feature 
engineered) would be desirable. In theory, this could currently be done within the current 
MAgEC framework by perturbing combinations of features simultaneously, but the 
computational cost for most models would be prohibitive.  
 
6.1.5. Conclusion 
MAgEC provides an intuitive explanation of arbitrarily complex models for anyone that 
is familiar with regression coefficients. It provides explanations on both the global and local 
levels and also adds in a population level (or similarity between cases) explanation. While it is 
perhaps most useful in the context of deep learning, MAgEC can also be used to extend utility of 
Random Forests and SVMs and allowing what many different model types have been learned to 
be compared directly. When MAgECs are visualized as a heatmap for temporal models they 
make it possible to understand complex temporal trends from a single image. 
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Chapter 7 
DeepMANN 
7.1. Mann 
A Deep Learning Pipeline to predict phenotype from microarray data 
 
7.2.1. Background/Introduction 
The ability to predict phenotype from genotype is extraordinarily valuable. 
Diagnostically, it could be used to determine which treatment regime is best suited to an 
individual. Prognostically, it could be used to begin interventions long before a phenotype was 
visible, thus potentially improving or even preventing disease states. Pharmaceutically, it could 
be used to select the drug or combination of drugs most likely to maximize effect and minimize 
adverse reactions. 
Microarrays provide a fast and inexpensive way to sample the genome of an individual 
by checking to see how many copies of the most commmon nucleotide that individual posses at 
each of ~500k positions. Since humans are generally assumed to be exclusively diploid, theses 
arrays record 1 or 3 possible values at each position: 0 (the nucleotide at neither chromosome 
matches the reference), 1 (a nucleotide on 1 chromsome matches but the other does not), 2 (both 
match).  
Genome Wide Association Studies (GWAS) seek to identify genetic differences between 
individuals that possess (cases) or lack (controls) a phenotype of interest by collecting 
microarray data on large numbers of individuals and then looking at each position on the 
microarray and comparing the prevelence of the number of zero's one's and two's between the 
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cases and controls. The phenotye of interest is most often the presence of a particular disease or 
medical condition, or its absence.  
The initial goal of GWAS was to increase biological understanding and discover targets 
for potential treatments by identifying a small number of powerful driver mutations (Single 
Nucleotide Polymorphisms or SNPs) that controlled a given phenotype. This was based on the 
assumption that most phenotypes possessed a small number of genetic determinants whose state 
determined the phenotype. The search was for a small number of drivers, each with an enormous 
effect size. 
This approach necessitates that individual mutations be both relatively common in the 
population (so that they can be discovered among cohorts of thousands) and capable of 
dramatically altering the phenotype.  
Studies over the last two decades have increasingly shown that the genetic contribution to 
human phenotypes is influenced by a large number of polymorphisms, most of which have a 
relatively small effect size. Given this knowledge, new approaches were developed that modeled 
phenotype as the additive effect of an increasing larger number of polymorphisms. Theses 
approaches search for a large number of drivers, each with a small effect. Some methods, such as 
Fast-LMM can even look at the entire set of microarray data to approximate the effect of each of 
the ~500k SNPs on an array.  
The short coming of these approaches is the fundamental assumption that mutations have 
a linear relationship with a phenotype. Biology is fundamentally complex: each stage in central 
dogma inolves multiple pathways, and a single gene (coded by thousands of nucleotides) within 
one pathway is often involved in multiple other pathways. Thus, while there are a small number 
of exceptions where a single mutation is so disruptive that it's effect is synonymous with a 
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change in phenotype, the rule is that there is an extraordinarily complex and non-linear 
relationship between DNA (nucleotides) and phenotype.  
For nearly all common or complex diseases, it is not possible to predict phenotype from 
genotype at a clinically useful level. However, microarray data is extremely plentiful. A 
methodolgy capable of overcoming the shortcomings of GWAS and additive effect assumptions 
by capably modeling the complex non-linear relationship between genotype and phenotype could 
have significant clinical impact.  
Deep Neural Networks (DNNs) have come to prominence in many different fields over 
the last 5 years because they are remarkably capable of identifying complex non-linear patterns. 
This capability comes from applying a series linear mappings followed by non-linear 
transformations which allows heirarchical learning of features. In the space of genetics this could 
allow the equivalent of using nucleotide mutations as raw inputs, combining those mutations into 
pathways, then learning pathway interactions, and finally determining which set(s) of pathways 
and pathway interactions are associated with healthy or disease states. (Obviously important to 
note that a DNN isn't going to re-create a biological pathway, it's going to create a function that 
models something equivalent to a pathway.) 
DNNs are not magical, they learn slowly and require a large number of samples to 
effectively train. Empiracally, this often necessitates tens of thousands of samples per class. 
Furthermore the complexity of a DNN is directly limited by the relative number of input features 
to the number of samples presented for learning. This means that number of input features must 
be kept reasonably small and can only grow as the number of sample grows.  
DNNs may be well suited for GWAS/microarray data since studies already exist that 
contain the tens of thousands of samples nessary to train a network capable of modeling complex 
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non-linear relationships. Conducting further microarray studies is inexpensive and DNNs can be 
updated with new knowledge one sample at a time, there's no need to retrain the entire network 
when new data becomes available. 
 
**Scope** 
 
Complex diseases are by definition complex. Not only with complex genetic components, 
but also with complex environmental components, and even complex gene-environment 
components. Currently, deepMANN considers only the genetic contribution to phenotype and 
therefore it's predictive power is thresholded at a maximal upper bound set by each disease's 
heredity. Thus, while we hope the approach will be equally successful at uncovering the genetic 
patterns underlying diverse diseases, the ability to predict phenotype given genotype should be 
expected to vary considerably from disease to disease. Additionally, the true genetic contribution 
the overwhelming majority of human phenotypes is unknown. While this makes it difficult to 
quantify the method's absolute performance, it is fairly simple to determine its relative 
performance by comparing its predictive power to the current best practices. 
Here we assess the predictive power of DNNs using a small number of SNPs and highly 
complex non-linear functions and compare it to Fast-LMM which uses the additive effects of all 
SNPs on the microarray. 
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7.2.2. Methods (Reader's Digest Version) 
Microarray data was downloaded from the Welcome Trust Inflammatory Bowel Disease 
(IBD) cohorts comprised of 14925 individuals of which there were approximately 1800 cases 
and 13125 controls. The data came divided into a BED file containing the polymorphism data 
and a text file containing the phenotype information for each inidividual; labeling them as either 
a case or control.  
The order of the individuals was shuffled so that cases and controls were randomly 
interspersed. The complete dataset was then split the into a training cohort comprised of 80% of 
the individuals (12000 members) and a testing cohort comprised of the remaining 20% of 
individuals (2925 members).  
Due to the large class imbalance, the primary metric that was used to assess model 
performance was area under the receiver operating curve (auc_roc).  
 
7.2.3. Data Preparation & Model Fitting 
**FAst-LMM** 
The FAast-LMM model was fit on the training cohort using all 360,000 SNPs present 
within the BED file. The model was first tested on the training cohort to ensure that the fit had 
occurred correctly and then tested on the testing cohort to determine the predictive power of the 
model out of sample.  
 
**Deep Neural Networks** 
Since the DNNs would be unable to effectively learn using all 360k SNPs, initial feature 
selection was done by performing GWAS on the training cohort using linear regression from the 
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FAst-LMM package. The top-N SNPs (where N was either 500 or 2000) were selected and the 
genotypes for each SNP were collected on all individuals. The SNPS were then arranged in order 
by chromosome number and chromosome position. Different models were built using different 
types of DNNs including Convolutional Networks and Multilayer Perceptrons each both 500 and 
2000 SNPs.  
The models were first tested on the training cohort to ensure that the fits had occurred correctly 
and then tested on the testing cohort to determine the predictive power of the model out of 
sample. 
 
**DNN Architecture Logic** 
Three different DNN architectural structures were developed representing two 
conceptually different approaches and a middle ground between them.  
1. Pure Convolutional Network 
2. Convolution followed by Neural Network 
3. Multilayer Perceptron 
 
Convolutional networks (convNet) have defined the success of Neural Networks in recent 
years. They comprise the architecture that has resulted in ultra-human performance on image 
recognition tasks and are also used in state of the art speech recognition and streaming vision 
such as that used by self-driving vehicles. Conceptually, convNets operate by searching for 
localized patterns within the input. An eye is an eye, regardless of whether it appears in the top, 
bottom, or middle of a picture. At the next level in the heirarchy, two eyes next to each other 
with a nose in the middle can make up a face. ConvNets were used as a deepMANN architecture 
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for two reasons; as a potential filter for linkage disequilibrium (LD) and to capture any localized 
patterns in mutation. ConvNets have recently been showing success when employed on DNA 
sequence data, however since microarrays do not sample the genome at equa-distance positions it 
is unlikely that deep convNets will be the optimal solution as convNets discard all but the most 
powerful local signals.  
Multilayer Perceptrons (MLPs) consist of multiple fully connected layers of neurons. 
They care nothing about locality and instead search for global patterns using the entirty of the 
data from the previous layer in the current layer. In general, MLPs are capable of modeling much 
more complex functions than convNets can, but this comes at the expense of requiring much 
more computational resources and raw input in order to effectively learn. The additional 
computation necessary is primarily memory: MLPs have considerably more absolute parameters, 
additionally no parameters within an MLP are redundant as is the case for convNets, and finally 
MLPs do not discard any information during forward propogation while convNets generally 
discard the majority of their data. The fact that MLPs have more absolute parameters to learn is 
what necessistates the greater volume of raw input.  
A middle ground between the convNet and the MLP was reached by effectively attaching 
a deep MLP to a relatively shallow convNet with goal of using convolution primarily to filter LD 
and then using the MLP to model the heirachrical global complex non-linearity by which 
genotype becomes phenotype.  
 
**Optimization Choices** 
Binary cross-entropy was selected as the loss function to optimize. The class imbalance, 
which at only 8:1 is much smaller than that observed in most biological settings, initially 
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prevented the DNNs from being to learn anything at all. The solution was to modify the loss 
function so that it more heavily penalized mistakes made on the under represented class by 
multiplying the loss for that class by the ratio of the class imbalance. This proved sufficient to 
allow the maximum network performance. Penalizing the loss at a ratio greater than the class 
imbalance did not result in additional gains in the prediction of the under represented class (even 
when the penalty was 10x the class ratio, or ~80x normal). 
ADAM (Adaptive Moment Estimation) was chosen as the learning alogrithm; it is one of 
the current best performers in the industry and literature (as of Aug 2016) and does especially 
well if the input data is sparse (such as when using one-hot encoding for the convolutional 
networks). ADAM does per parameter optimization. Nodes that receive large gradients will see 
their effective learning rate reduced. Nodes that receive small or infrequent updates will see their 
effective learning rate increased. Adam accomplishes this by storing a running average of 
gradients (1st and 2nd momentum). So the downside is that it requires more memory. The 
enormous benefit is that it converges very quickly which not only speeds up training but also 
reduces the liklihood of being trapped in a local minima.Additionally, ADAM requires no user 
adjustment of learning rate or momentum to achieve optimal performance.  
 
**Architecture Development Process** 
Initial network structure was decided by considering the size of the raw input and 
attempting to adapt and combine the best practices from the fields of regulartory genomics and 
computer vision. Initially the training process was manually monitored and architecture 
adjustments were made to identify the number, type, and order of layers that resulted in 
reasonable performance. This was followed by grid searches to optimize the network’s 
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hyperparameters such as number samples to use prior to gradient descent update, number of 
training cycles, strength and type of regularization, the number and size of filters and pooling 
sizes for the convolutional layers, and number of neurons in each layer.  
 
7.2.4. Results 
#### GWAS Results 
This is included only for reference purposes. It's the results of the simple regression and 
shouldn't be treated too seriously. 
 
Figure 7.1: GWAS Results 
 
#### FAst-LMM 
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 Figure 7.2: FAst-LMM In Sample Performance 
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Figure 7.3: FAst-LMM Out of Sample Performance 
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 #### DNNs 
There were multiple different architectures, each with very different parameters that all 
converged to the same ROC scores. These are representative examples that reached the peak roc.  
 
**MLP** 
 
 
Figure 7.4: MLP2000 In sample ROC 
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Figure 7.5: MLP2000 Out of sample ROC 
 
Parameters: 
* initialization = random uniform distribution 
* dropout_rate = 0.5 
* l2_regularization amount = 0.4 
* input_layer_neurons = 2000 
* neuronsfc1 = 300 
* neuronsfc2 = 1500 
* neuronsfc3 = 1500 
 
**ConvNet + DNN** 
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Figure 7.6: conv_500 out of sample 
 
Parameters: 
* dropout_rate = 0.5 
* neurons = 100 in each dense layer 
* zero padding used preseve dimensions 
* 16 filters, each 3x3 
* Pooling Size = 1x2 (max of 2 nearest) 
 
**Quick Summary:** 
The linear model had zero recall out of sample. Multiple architectures of DNNs outperformed 
had an roc_auc of .63 (Overall accuracy was between 69:71%).  
 
7.2.5. Discussion 
The DNNs reached a clear limit at .63 roc_auc, although the conv+NN converged to it 
using only 500 SNPs as input, while the MLP required 2000 to reach it.  
This limit is likely to have been caused by either of 2 factors (or a combination): 
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1. *Not enough samples to learn additional complexity*: Class imbalance aside, with only 
~1600 examples in the positive class to learn from the network is severely hampered. 
Reasonably complex DNNs empirically require a minimum of around 10,000 examples 
per class. Having a greater number of samples, even while maintaining the class 
imbalance, could allow exploitation of a more complex architecture which could provide 
greater predictive power. 
2. *Genetic signal reached*: It is possible that SNP data is only capable of .63 roc_auc for 
IBD. 
 
7.2.6. Future Directions 
1. Use deepMANN on more interesting phenotypes with larger sample sizes 
2. The ultimate medical goal is not to predict phenotype from genotype, but to create the 
most accurate prediction possible using all of the available data. DNNs have proven to be 
well suited to build strong multi-modal models. The current approach sets a foundation 
that be easily expanded upon. 
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Chapter 8 
Philter 
 
8.1. Philter 
8.1.1. Abstract 
There is a great and growing need to ascertain what exactly is the state of a patient, in 
terms of disease progression, actual care practices, pathology, adverse events, and much more, 
beyond the paucity of data available in structured medical record data. Ascertaining these harder-
to-reach data elements is now critical for the accurate phenotyping of complex traits, detection of 
adverse outcomes, efficacy of off-label drug use, and longitudinal patient surveillance. Clinical 
notes often contain the most detailed and relevant digital information about individual patients, 
the nuances of their diseases, the treatment strategies selected by physicians, and the resulting 
outcomes. However, notes remain largely unused for research because they contain individually 
identifying data, or Protected Health Information (PHI). Previous clinical note de-identification 
approaches have been rigid and still too inaccurate to see any substantial real-world use, 
primarily because they have been trained with too small medical text corpora. To build a new de-
identification tool, we created the largest manually annotated clinical note corpus for PHI and 
develop a customizable open-source de-identification software called Philter (“Protected Health 
Information filter”). Here we describe the design and evaluation of Philter, and show how it 
offers substantial real-world improvements over prior methods. 
Keywords: Natural Language Processing (NLP); Electronic Health Records (EHR); De-
identification; Clinical Notes; Protected Health Information (PHI);  
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8.1.2. Introduction 
Structured EHR fields, primarily comprised of elements such as high-level demographics 
and billing codes (ICD), are currently the most utilized in determining the state of a patient, in 
terms of clinical care details or disease state. Many of these fields are often used in clinical 
research, and are now starting to be used to determine human phenotypes1 for genome-wide 
association studies, and can be used to facilitate automated improvements of healthcare decision 
making2. However in many cases this information is not detailed enough to provide appropriate 
insights. Additionally, procedural, diagnostic, and medication billing coding are often 
incomplete, inconsistent, subjective, and inaccurate (often due to the needs of billing prioritizing 
over the needs of science), and this could even lead to false insights3,4. Clinical notes often 
contain the richest and most relevant information available about disease phenotypes, treatments, 
and outcomes as well as the clinical decision-making process. This written medical narrative 
frequently captures patient experience and event ordering timelines. To date, there have been 
many studies that have successfully used data from clinical notes for discoveries, including 
detection of drug adverse outcomes5, identification of off-label drug use6, surveillance of disease 
states7, and identification of clinical concept relatedness8.  
With nearly the entire United States healthcare system now adopting electronic health 
records (EHRs), but with most of the actual clinical details captured in these free-text notes, 
transforming information contained within clinician notes into a computable resource is essential 
for medical research and improving patient care. However, clinical notes contain legally 
Protected Health Information (PHI), which prevent their use in most research applications.  
Removal of PHI from clinical notes is a challenging task because the potential number of 
words that could be PHI are limitless. There are many different methods for recording and 
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formatting patient note data across the health system landscape, and each health system serves a 
distinct patient population resulting in differences in the distribution of types of PHI across 
health systems9 and the probability that a given word is PHI or a medical term (e.g.: ‘MA’). 
The current state-of-the-art in de-identification systems still have real-world weaknesses 
because there are only a small number of corpora openly available for algorithm development 
and testing10-14. Priorities around de-identification software performance in recent years have 
been driven largely by de-identification competitions, most notably the Integrating Biology and 
the Bedside (i2b2) competitions in 2006 and 2014, which have emphasized a balanced approach 
of information retention and patient privacy, instead of national guidelines 
(https://www.hhs.gov/hipaa/for-professionals/privacy/special-topics/de-
identification/index.html) which focus exclusively on privacy. It is clear that real-world 
performance is generally still below the threshold of compliance regulations for removing PHI, 
resulting in a lack of broader use of these tools to de-identify notes for research9,15 ,16. Every 
piece of PHI not identified and removed represents a potential violation of patient privacy and 
also a potentially expensive lawsuit. Even at 95% recall (i.e., percent of PHI removed), the 
amount PHI still remaining across millions of clinical notes would be staggering. 
With an incredibly diverse patient population being treated at the University of 
California, San Francisco (UCSF), yielding over 70 million clinical notes collected within our 
Electronic Health Records (EHR), we required an efficient, accurate, and secure method for 
removing PHI from notes in order to make these data usable by researchers while minimizing the 
risk of PHI exposure. We developed a privacy-centric approach to removing PHI from free-text 
clinical notes using both rule-based and statistical NLP approaches. The algorithm utilizes an 
overlapping pipeline of methods that are state-of-the-art in each application including: pattern 
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matching, statistical modeling, blacklists, and whitelists. We built this software tool as a self-
contained system that could be deployed on any major computing platform and can operate 
without an internet connection, allowing it to be run in secure environments. 
We have called this algorithm Philter (Protected Health Information filter). In this work, 
we describe the engineering of Philter and its evaluation against other systems. As we have 
discovered most existing tools in this field do not have actual open source availability, we have 
released Philter as open source code, and envision tens of thousands of health systems finding it 
useful. 
 
8.1.3. Online Methods 
8.1.3.1. Corpora: UCSF Corpus 
To create the UCSF corpus of clinical notes, 4,500 notes were randomly selected from 
over 70 million notes from all departments at UCSF by assigning a hash identity to each note ID, 
randomly permuting the order of the hashed ID, then randomly selecting 4,500 hashed note IDs. 
Words were then manually annotated for PHI-categories by one of our three trained annotators. 
The annotators used Multi-document Annotation Environment (MAE)17. The MAE tool was 
configured with PHI elements following the HIPAA Safe Harbor guidelines with a couple of 
additional categories to identify provider information (Supplemental Table 8.1). 4,500 notes 
were annotated twice, with a second annotator reviewing and correcting the mark-up of the first 
annotator and Inter-Rater Reliability was calculated. When in doubt, annotators chose the more 
conservative option, for example marking an unclear name as belonging to a patient vs a 
physician. We generated a distribution of the randomly sampled notes and found more than one 
hundred note categories, note types, departments of origin, and provider specialties. We 
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randomly assigned 2,500 notes to use for the development of a new de-identification algorithm 
(see Supplemental Table 8.2 for a distribution of the departments represented) and 2,000 notes to 
test algorithm performance (Supplemental Table 8.3). 
The UCSF Committee on Human Research approved our study protocol [study # 16-
20784]. 
 
8.1.3.2. I2b2 corpus 
The i2b2 2014 de-identification challenge test corpus consists of 514 notes and was 
downloaded on July 18, 201710,11. However, annotations of words as either safe or PHI within 
this corpus do not exactly follow the HIPAA guidelines for Safe Harbor, specifically in regards 
to locations and dates18. We therefore changed the annotations for words from the following 
categories: years in isolation, seasons (e.g. winter, spring), days of the week, patient/doctor 
initials in isolation, country names and ages under 90 from PHI to safe. The i2b2 2014 corpus 
replaced real PHI with surrogates. In a few instances, the surrogate values are for patient 
identification numbers were unrealistic, being four digits or less. These were removed.  
 
8.1.3.3. Evaluating De-identification Performance 
If PHI is allowed through a de-identification system, that yields a recall error, in that the 
PHI was not found. If safe words are obfuscated, that yields a precision error, in that extra text 
was unnecessarily removed. Since preventing exposure of PHI is our highest priority, we wanted 
to devise a system that minimized recall errors, even at the expense of greater precision errors. 
Each PHI word that evades detection increases the risk of patient re-identification. 
Therefore, we evaluate performance at the word-level. In this analysis, we count as True 
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Positives (TP) those PHI words that were correctly labeled as PHI while the False Positives (FP) 
are non-PHI words that were incorrectly labeled as PHI. Likewise, True Negatives (TN) are non-
PHI words correctly labeled as non-PHI while False Negatives (FN) are PHI words incorrectly 
labeled as non-PHI.  
Since we chose to optimize our method to maximally maintain patient privacy, we chose 
recall as our primary measure of performance (Equation 1), which represents the portion of PHI 
words that were identified correctly:  
 
 Recall = 𝑇𝑃 𝑇𝑃 + 𝐹𝑁⁄  (1) 
 
 
However, de-identified clinical notes only have value if they retain as much non-PHI 
information as possible. Thus, we also measure precision (Equation 2), which represents the 
portion of filtered words that were non-PHI: 
 
 𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 =  𝑇𝑃 𝑇𝑃 + 𝐹𝑃⁄  (2) 
 
To account for precision, we selected the F2 score (Equation 3) as our secondary 
performance measure, which is a weighted average of recall and precision that values recall 
twice as much as precision: 
 
 𝐹2 = 5 ∗ 𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 ∗ 𝑅𝑒𝑐𝑎𝑙𝑙 (4 ∗ 𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛) + 𝑅𝑒𝑐𝑎𝑙𝑙⁄  (3) 
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8.1.4. Algorithm 
8.1.4.1. Algorithm Concept and Overview 
The categories of PHI, the values of PHI, and the context surrounding PHI within a note 
can change drastically between types of notes, between departments within a health system, and 
between different health systems. In contrast to this, we believe that words that are not PHI have 
considerably less variability. Therefore, we started with an approach of identifying words that 
are not likely to be PHI. Approaches to identify words that are likely to be PHI were then 
incorporated into the algorithm for additional security and precision.  
 
8.1.4.2. Algorithm Control, Customization, and Output 
To optimize ease of use and modularity, while ensuring that the complete algorithm 
performs as expected, the pipeline is controlled by a simple text configuration file in the JSON 
format. We store the position of each character in memory so that tokens identified as PHI may 
be replaced with an obfuscated token of exactly the same length (e.g.,: ‘John Smith’ becomes 
‘**** *****’). Therefore, the original structure of the note is perfectly preserved, with the 
exception that asterisks in the original note are replaced with spaces. The priority with which a 
token is marked as PHI or safe is dictated by the order of processes in the configuration file and 
is entirely customizable. We built an evaluation script that automatically compares de-identified 
notes to annotated gold-standards at the character level to quantify global and PHI category-
specific performance.  
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8.1.4.3. Algorithm Pipeline 
At the beginning of the pipeline, a custom script tokenizes individual words within each 
note by separating them on whitespace and symbols (i.e., -, /, #, &, periods, etc). Next, short 
phrases that have a high probability of not being PHI are identified using pattern matching with a 
custom library of 133 “safe” regular expressions. Then, a custom library of 171 regular 
expressions is used to identify predictable PHI entities such as salutations, emails, phone 
numbers, dates of birth, social security numbers, and postal codes. In both cases, the regular 
expressions search for specific words, phrases, and/or numbers and utilize the immediate context 
surrounding each word to identify matches. For example, if a number appears adjacent to the 
word ‘age’ or ‘years old’, that number is interpreted as an age and is PHI if it is greater than or 
equal to ninety, as per HIPAA guidelines for Safe Harbor methods. On the other hand, a number 
referring to dosage (e.g., 50 mg) is not interpreted as PHI.  
At this stage, the Python NLTK module is used to tag each word with a part of speech 
(POS) to address the challenge of dealing with words that could be either safe or PHI, using 
statistical modeling to determine the structure of each sentence and document. For example, the 
word ‘White’ in the context of ‘White fluid found at...’ is an adjective and therefore safe, while 
‘Patient John White presents with...’ is a proper noun and is PHI.  
We assembled a blacklist of names using last names occurring 100 or more times in the 
2010 U.S. census, and first names occurring five or more times for each year of birth between 
1879-2017 from the U.S. Social Security website. To minimize occurrences of names that are 
also common words (i.e. new, walks, knee, home, child, etc.) in the blacklist, we removed a total 
of 855 words from the blacklist that were the greatest contributors to precision errors during 
training (complete documentation of blacklist creation is available on the public github 
 106 
repository). All names added to the final blacklist were tokenized on whitespace and symbols, 
and converted to lowercase. The blacklist was separated into a first names blacklist and a last 
names blacklist, and the two lists were incorporated into the full pipeline in succession. During 
the blacklist stage of PHI-searching, if a token is in at least one of the blacklists and is labeled as 
a proper noun by NLTK (e.g.POS tag = NNP), it is marked as PHI. 
Next, an additional name removal step is implemented using a combination of regular 
expression and blacklist matching. We created a custom library of 4 regular expressions that 
search for common last name patterns in clinical notes (e.g. Jane Doe or Doe, Jane), and 
potential names are marked as PHI if an adjacent token was previously marked as PHI by a 
blacklist.  
At this point, the pipeline employs a safety mechanism to catch PHI that occurs in 
unexpected formats, such as previously unseen names, words with incorrect POS tags, or 
misspellings. This is accomplished by identifying previously unlabeled (label = PHI/Safe) tokens 
that are most likely not PHI. This is accomplished using a custom whitelist of ~195,000 tokens 
comprised of medical terms and codes extracted from common medical word banks and 
ontologies (e.g., UMLS, SNOMED, MeSH, etc.), common medical abbreviations, the 20,000 
most common English words and an additional list of common English verbs with varied tenses. 
All Social Security and 2010 Census names were removed from the whitelist, and some common 
English and medical words were then added back to the whitelist to maintain acceptable 
precision measurements (Complete whitelist documentation can be found on the github 
repository). All tokens that have not already been categorized as PHI or Safe by an earlier 
portion of the pipeline, with the exception of tokens with numeric POS tags, are passed through 
the whitelist. 
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A final active filtering process is used to identify patient and provider initials. We created 
a single regular expression that searches for initials patterns in clinical notes (e.g., Doe, J. or Jane 
S. Doe), and these regex matches are marked as PHI if one or more adjacent tokens were 
previously marked as PHI by a blacklist. 
At the conclusion of the pipeline a token can have one of three possible labels: marked 
for exclusion, marked for inclusion, or unmarked. To maximize patient privacy, only words 
marked for inclusion are retained (Figure 8.1). 
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Figure 8.1: Philter Algorithm pipeline 
 
 
 
 
 
 
Mr. John Wayne consulted Drs. Susan A. Wallice nd Nick White for his 
headache on 04/23/16, complaining of 10/10 pain.
Mr. John Wayne consulted Drs. Susan A. Wallice nd Nick White for his 
headache on **/**/**, complaining of 10/10 pain.
Mr. **** ***** consulted Drs. Susan A. Wallice nd Nick White for his 
headache on **/**/**, complaining of 10/10 pain.
Mr. **** ***** consulted Drs. ***** A. ******* nd **** White for his headache 
on **/**/***, complaining of 10/10 pain.
Whitelist to keep 
medical terms and 
common English 
words
Mr. **** ***** consulted Drs. ***** A. ******* nd **** **** for his headache 
on **/**/**, complaining of 10/10 pain.
Mr. **** ***** consulted Drs. ***** *. ******* ** **** **** for his headache on 
**/**/**, complaining of 10/10 pain.
Mr. John Wayne consulted Drs. Susan A. Wallice nd Nick White for his 
headache on 04/23/16, complaining of 10/10 pain.
Regex to keep 
medical results found 
in a verifiably safe 
context
Regex for removing 
words following 
patient  salutations
Regex for removing 
common date 
patterns
Blacklists to remove 
names that are 
proper nouns (NNP)
Safety net: remove 
any unmarked word 
tokens
Regex to catch 
initials adjacent to 
words marked by 
Blacklist
Regex to catch 
names adjacent to 
words marked by 
Blacklist
Mr. **** ***** consulted Drs. ***** A. ******* nd **** ***** for his headache on 
**/**/**, complaining of 10/10 pain.
Mr. **** ***** consulted Drs. ***** *. ******* nd **** **** for his headache 
on **/**/**, complaining of 10/10 pain.
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8.1.4.4. Optimization 
2500 notes in the UCSF development corpus were used to develop the optimal Philter 
algorithm. Each portion of the pipeline, as well as the overall ordering of the pipeline, was 
modified to obtain the greatest overall performance metrics. Examples include changes to regular 
expression patterns, the tokens present in the White and Black lists, and the POS tags used to 
match against the lists. Optimization was done iteratively, developing against 500 notes at a time 
from the development set, testing against the next 500 notes in the development set, then 
repeating, growing the size of the development set by the previous 500 notes each time.  
 
8.1.4.5. Comparators 
Ferrandez et al.9, performed a head-to-head comparison of multiple de-identification 
systems on multiple corpora, which revealed that the PhysioNet de-identification tool11, had the 
best out-of-the-box performance. To identify PHI, the PhysioNet algorithm uses a combination 
of regular expressions and three types of lookup dictionaries (known names of patients and 
hospital staff, generic names of people and locations, and common words along with UMLS 
terms considered by their team unlikely to be PHI).  
We selected the PhysioNet de-identification tool as the strongest comparator that met our 
criteria and downloaded the source code from PhysioNet ’s14 website (https://www.PhysioNet 
.org/physiotools/deid/) on February 12, 2017. 
The National Library of Medicine’s Scrubber tool, first published in 201319 takes the 
approach of maximizing recall and valuing real-world generalization over public challenge 
competition results. It has been continually revised and improved since its initial creation and 
investigators have even launched a trial20 with updates as recent as 2018. The tool makes use of 
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other public tools, including Apache’s cTAKES21 and UIMA projects22, to compare the 
likelihood of words being PHI based on their relative frequency of appearance in public 
documents such as medical journals and LOINC codes to private physician notes under the 
reasonable assumption that words that appear in public documents are unlikely to be PHI. We 
selected the NLM Scrubber tool as our second comparator and downloaded the most recent 
version (v.18.0928) from the NLM website (https://scrubber.nlm.nih.gov/files/). Unfortunately, 
NLM Scrubber software does not maintain the original character alignment of scrubbed notes 
and comes with no method to automatically evaluate its performance against annotated notes. 
We had to design an evaluation script for this software and have made the script available to the 
community on our GitHub repository.  
 
8.1.4.6. Framework for secure de-identification and evaluation 
Figure 8.2 outlines the environment we designed to build and run Philter on clinical notes 
while ensuring security of the original notes and providing a framework for reporting PHI that 
was not filtered by the algorithm.  
To ensure security, clinical notes were kept on a server with an encrypted drive protected 
behind an institutional firewall and through access-controlled VPN at all times from initial 
software development through institutional release. Access to the server was only permitted via 
password-protected SSH protocol from points inside the VPN, and only from devices which 
themselves had encrypted stores or hard drives. The raw clinical notes were loaded onto the 
server through a Clarity-level text document extraction from UCSF's Epic EHR system. 
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Figure 8.2: De-identification Ecosystem 
 
 
8.1.4.7. Measuring compute time 
We calculated the run time of our pipeline using batches of 500 notes on a 32 core Linux 
machine with 16GB of RAM using the native Linux Time function, ‘time’, to estimate the 
feasibility of running Philter at a large scale. We conducted two experiments. First, a single batch 
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of 500 notes, with a total size of 2.2Mb, was run as single process and timed. Second, 20 batches 
of the 500 notes were run simultaneously as multiple processes and timed. 
 
8.1.4.8. Sensitivity Analysis 
In addition to Recall and F2 performance, we were interested in we were interested in the 
distribution of PHI across each category of PHI along with the number of TPs and FPs resulting 
from the best de-identification tool.  
 
8.1.4.9. Open source code 
The Philter package is written in machine-portable Python. The package can be installed 
via PIP, the Python package installer, and the source code along with detailed design descriptions 
as well as installation and use instructions can be obtained through the public repository open-
sourced, under an MIT License (https://github.com/beaunorgeot/philter-ucsf-beta).  
 
8.1.5. Results 
The Inter-Rater Reliability, for PHI vs Safe tokens, between first and second pass 
annotators in the UCSF corpus was greater than 99.99%, with the second annotator identifying 
an average of 39 additional PHI tokens and converting an average of 21 tokens from PHI to Safe 
per 500 notes.  
We compared overall recall and precision and per-PHI-category Recall across the three 
algorithms (Physionet, Scrubber, and Philter) on two corpora; the 2,000 note UCSF test corpus 
mentioned above and the publicly available 514 note 2014 i2b2 test corpus. 
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Primary and Secondary result metrics on both corpora are displayed in Table 8.1, with 
precision listed as a reference. On the UCSF test corpus: Physionet had a recall of 85.10% and an 
F2 of 86.15%, Scrubber had a recall of 95.30% and an F2 of 91.59%, and Philter had a recall of 
99.46% and an F2 of 94.36%. On the 2014 i2b2 test corpus: Physionet had a recall of 69.84% 
and an F2 of 73.05%, Scrubber had a recall of 87.80% and an F2 of 85.22%, and Philter had a 
recall of 99.92% and an F2 of 94.77%.  
 
Table 8.1: Performance Comparison of Tools and Corpora 
 UCSF I2B2 
 P R F2 P R F2 
PHIlter 78.28 99.46 94.36 78.58 99.92 94.77 
Physionet 90.62 85.10 86.15 89.49 69.84 73.05 
Scrubber 79.24 95.30 91.59 76.26 87.80 85.22 
Note: P = Precision, R=Recall.  
 
Philter also outperformed both of the other algorithms for each category of PHI on both 
corpora, in addition to having the highest overall recall (See Table 8.2). 
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Table 8.2: Remaining PHI Analysis by Tool, UCSF Test Corpus 
PHI Category 
Instances of 
PHI 
remaining 
(PHIlter) 
Instances of 
PHI 
remaining 
(Physionet) 
Instances of 
PHI 
remaining 
(Scrubber) 
Age >= 90 0 0 0 
Patient_Vehicle_or_Device_Id 0 18 0 
Patient_Account_Number 0 35 4 
Patient_Medical_Record_Id 0 445 0 
Patient_Social_Security_Number 0 0 6 
Patient_Phone_Fax 0 0 1 
Patient_Initials 2 120 132 
Patient_Name_or_Family_Member_Name 6 211 93 
Patient_Address 7 25 16 
Patient_Unique_ID 20 442 34 
Email 0 1 1 
URL_IP 4 20 153 
Date 7 257 269 
Provider_Certificate_or_License 0 276 99 
Provider_Name 12 546 90 
Provider_Initials 12 236 217 
Provider_Address_or_Location 43 1597 210 
Provider_Phone_Fax 45 49 43 
Note: PHI counts for PHIlter, Physionet and Scrubber performance on the UCSF corpus. 
Instances of PHI represent single tokens within the span of multiple or single-token items of PHI. 
Patient-only PHI is highlighted in blue, provider-only PHI is highlighted in yellow, and 
patient/provider PHI is highlighted in green. 
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Table 8.3: Remaining PHI Analysis by Tool, I2B2 Corpus 
PHI Category 
Instances of PHI 
remaining (PHIlter) 
Instances of PHI 
remaining 
(Physionet) 
Instances of PHI 
remaining 
(Scrubber) 
AGE 0 1 0 
DEVICE 0 6 0 
MEDICALRECORD 0 524 18 
PATIENT 2 154 92 
DATE 0 4590 1587 
FAX 0 2 0 
PHONE 0 31 67 
ZIP 0 3 1 
USERNAME 1 92 92 
STREET 2 27 21 
LOCATION-OTHER 2 9 12 
IDNUM 2 297 206 
CITY 2 14 52 
DOCTOR 5 197 186 
PHI counts for PHIlter, Physionet and Scrubber performance on the I2B2 corpus  
 
8.1.5.1. Sensitivity Analysis: Distribution of PHI and Philter Recall by Category 
The raw count of PHI varied noticeably between the two corpora, but Philter’s recall 
consistently generalized across the categories for each corpus (Supplemental Tables 4 and 5).  
Results of additional sensitivity analyses regarding the precision errors caused by each 
element of the algorithm pipeline (Supplemental Tables 6) and the impact of partial PHI removal 
(Supplemental Tables 7 and 8) and can be found in the Supplement.  
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8.1.5.2. Philter Compute Time 
The amount of real (wall-clock) time necessary to run 500 notes as a single process was 
323 seconds. The amount of real time necessary to simultaneously process 20 batches of 500 
notes, 10,000 notes total, was 401 seconds. 
 
8.1.6. Discussion 
8.1.6.1. Principal Results 
In this study we developed an algorithm, Philter, that utilizes an overlapping pipeline of 
multiple state-of-the-art methods and compared it to the two strongest real-world competitors on 
the basis of recall. Philter demonstrated the highest overall recall on both corpora, had the 
highest recall in each category of PHI on both corpora, and generalized well between the 
corpora. Philter’s recall on the 2014 i2b2 test corpus is the highest reported in the literature. A 
key design decision was the use of rules to separate PHI from Safe words while using a statistical 
method to improve precision. The overall size of the UCSF corpus at 4,500 manually annotated 
notes is the largest in the world that we are aware of. Likewise, the UCSF test corpus, at 2,000 
notes, is the largest corpus to be tested and reported in the literature.  
 
8.1.6.2. Limitations 
Despite Philter’s strong performance, with recall values equal to or greater than 99.5%, 
recall still was not perfect. The portions of PHI that were not identified were edge cases around 
existing patterns. For example, there were six total tokens that were missed for patient names in 
the UCSF test corpus. These tokens actually came from one single patient, whose name was six 
tokens long. The 6 token name appeared twice in one note, and each time Philter successfully 
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removed three of the names, likely making the actual patient’s name difficult or impossible to re-
identify. The solution to this and similar problems are almost trivially easy to fix but they 
underscore the need to test de-identification systems on very large and diverse corpora to 
continually discover and refine edge cases.  
The statistical portion of the pipeline was the most problematic from a precision 
perspective. The POS tagger frequently confused capitalized words, either at the beginning of 
sentences or all-capital words within sentences, as proper nouns. We found a very high overlap 
between common English words and medical terms (See, Whitelist) with names taken from the 
Census and Social Security. Precisely 16,095 names were found to be either medical terms or 
common English words. Therefore, an incorrect POS tag of NNP frequently resulted in a False 
Positive.  
The decision not to include institution-specific information, such as a map between 
patient names and note identification numbers, could be considered a limitation. At the time of 
development, we chose not to include such information for numerous reasons. First, our lists of 
patient names are messy (it was not uncommon for drug names to appear as patient names in our 
databases). Second, even after rigorous initial cleaning, our patient name lists only detected 80% 
of name PHI within the corpus. This is in part due to the fact that patient family member names 
frequently appear within notes and in part due to misspellings of names. Third, relying on the use 
of inside data would not produce an algorithm that was generalizable out of the box. We believe 
that patient name-to-note maps could make a small but valuable addition to the pipeline and we 
envision placing it prior to the Names Blacklist steps. However, at the time of this writing, 
despite extensive development, we still are not ready to incorporate them. If we find that doing 
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so improves performance in the future, we will provide the steps necessary to reproduce our 
process at other institutions on our github README. 
 
8.1.6.3. Comparison with Prior Work 
With more EHR systems being deployed across the world, there is still an incredible need 
for text processing tools, and de-identification is a key utility that can enable many readers and 
programmers to access those notes in a safer manner. While challenges and competitions have 
been run for nearly 10 years, there is still a pragmatic need for safe, efficient, open-source de-
identification tools. 
The field has been dominated by two separate approaches to designing de-identification 
algorithms. The first uses a rule-based system to detect PHI, while the second approach uses 
statistics to assign probabilities of PHI to words. Rule-based systems primarily use regular 
expressions and/or blacklists of words to tag PHI. Statistical methods employ machine learning, 
traditionally Conditional Random Fields and increasingly Recurrent Neural Networks, to learn 
patterns based on words and their context. Rule-based systems typically have better recall, while 
statistical methods typically have better precision. Rule-based systems are inherently predictable 
allowing their success and failures to be anticipated. Statistical systems are much faster to build; 
however, they are often difficult to interpret and performance on new data is more unpredictable. 
For example, the organizers of the 2006 i2b2 challenge discovered that the best performing 
algorithm in the competition, which utilized a statistical approach, suffered serious failures when 
de-identifying notes that came from the same hospital but were not drawn from the competition 
corpus23. 
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The sparsity of available notes for de-identification system development and testing has 
provided a tremendous challenge to developing robust de-identification approaches because the 
nature of PHI contained within a note may differ significantly depending on the hospital or 
department they were generated from. Ferrandez et al.9 demonstrated this by showing different 
proportions of categories of PHI distribution between the VHA, i2b2, and the Swedish 
Stockholm corpora. For example, Provider Names comprised only nine percent of the overall 
PHI in the VA corpus, but were nineteen percent of the PHI in i2b2, while there were no 
occurrences of Provider Names in the Stockholm corpus. Conversely, Patient Names make up 
only four and five percent of the VA and i2b2 PHI, respectively, but over 20 percent of the 
Stockholm corpus. ID Numbers were barely present in the VA corpus, totaling less than half of 
one percent of the PHI, but were responsible for more than twenty four percent of the PHI in the 
i2b2 corpus.  
Between the systems selected as comparators for this study, the Physionet tool is the 
oldest and most 'proven'; it has great precision but does not effectively remove PHI. Scrubber is a 
newer software and the designers traded precision to get much improved recall. Unfortunately, 
neither of these approaches can be easily modified. Since PHI varies widely from corpus to 
corpus and the needs of those performing de-identification are diverse, the lack of 
customizability of these tools presents real-world usability challenges. 
The NLM Scrubber software assumes that words appearing frequently in public 
documents are unlikely to be PHI, and although this assumption appears reasonable, it is not 
justifiable given our own findings. As mentioned above, we found over 16,000 names in the 
census and Social Security data that were either common English words or medical terms. This 
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may explain the 20X difference between Scrubber and Philter in the number of patient name 
tokens that remained after filtering.  
In addition to outperforming the comparators selected for this study, Philter sets new 
state-of-the-art recall results on the 2014 i2b2 corpus. The challenge winner, the Nottingham 
system, had a recall of 96.29 (Table 6: micro-averaged, token-wise, HIPAA category)12. Philter 
also demonstrates higher recall than the results reported for the more modern deep learning based 
de-identification systems (Dernoncourt et al.24 i2b2 recall 97.38; Lui et al.25 recall 93.8). 
Interestingly, the only publically available de-identification system used in the aforementioned 
competition, MITRE’s MIST tool26, faired quite poorly (HIPAA token recall of .805) even when 
supplemented with the well regarded Stanford NER tagger and pre-trained on an additional 
private corpus from Kaiser. 
It is fair to note that the i2b2 Challenge systems and the deep learning systems mentioned 
in this manuscript attempted to maximize F1 rather than recall. While we believe that this is a 
flawed approach within the de-identification community (considering recall is the primary 
concern from a patient privacy standpoint), we acknowledge that tuning these systems to 
maximize PHI removal could potentially improve their recall performance. 
As mentioned above, the POS tagger portion of the pipeline was the most problematic 
element from a precision perspective. Despite having lower recall and being subject to several 
statistical system challenges, such as lack of transparency and great risk of poor generalization to 
new corpora, we are excited by the very high precision of the deep learning approaches 
previously referenced24,25. We can imagine replacing the current NLTK POS tagger in the Philter 
pipeline with a deep learning version of the same. 
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8.1.7. Conclusions and Future Directions 
In summary, Philter providers state-of-the-art de-identification performance while 
retaining the majority of relevant medical information. We envision that PHI removal can be 
further optimized using a crowd-sourcing approach with lots of exposure to many hospitals and 
notes. For this reason, we have made Philter open-source and highly customizable. We believe 
the system is capable of 100% recall with enough exposure and community involvement. The 
simple to use software will accept any text file as input, is fully modular to allow the community 
to improve the algorithm or adapt it to each users’ specific needs, easy to evaluate, and 
executable in a secure environment. The software comes pre-configured, as the pipeline 
described in this manuscript, to produce the de-identification results that most closely follow 
HIPAA Safe Harbor guidelines. 
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8.2. Supplement 
8.2.1. Supplemental Background 
8.2.1.1. Motivation 
Initially, our plan was to identify a pre-existing de-identification system that we could use 
for this task. The number of open-source publicly available de-identification software systems is 
very small. We began the search for such a system by examining the HIPAA-defined, token-
based, recall results of the i2b2 2014 de-identification challenge12. Unfortunately, the top 
performing entry, Nottingham system27, was specifically fine-tuned for both the i2b2 dataset as 
well as the i2b2 evaluation script (using a post-processing script to modify tokens to maximize 
scoring), potentially limiting its generalization and resulting in over-optimistic assessment of 
performance. Additionally, the Nottingham system is not publicly available for use. 
Interestingly, the only publicly available de-identification algorithm that was used in the 
competition, MITRE’s MIST tool26, faired quite poorly (HIPAA token recall of .805) even when 
supplemented with the well regarded Stanford NER tagger and pre-trained on an additional 
private corpus from Kaiser.  
A wider literature review of post-i2b2 challenge identified a couple of potentially 
promising candidates that used Deep Recurrent Neural Networks and reported results on the i2b2 
2014 corpus for comparison24,25. However, the Lui et al.25 system is not publicly available in any 
form, and while the Dernoncourt et al.24 team have made available a Named Entity Recognition 
tagger based on their work, the de-identification system reported in their paper is not available.  
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8.2.1.2. Existing De-Identification Corpora 
There are a very small number of public corpora that have been labeled for PHI and are 
available to develop or test de-identification algorithms. The Informatics for Integrating Biology 
and the Bedside (i2b2) program, released a corpus of 889 discharge summaries as part of a 
challenge in 2006 to evaluate state-of-the-art systems for automatically targeting and removing 
PHI14. In 2008, PhysioNet released a corpus of 2,434 nursing notes that they used to build a 
software de-identification tool10,11. In 2014, i2b2 released another corpus as part of a new 
challenge consisting of 1,304 longitudinal clinical narratives derived from 295 hand-selected 
diabetic patients at risk for coronary artery disease 12,13. 
 
8.2.2. Supplemental Methods: UCSF Corpora 
Supplemental Table 8.1: PHI Categories 
PHI Categories 
Age >= 90 
Patient_Vehicle_or_Device_Id 
Patient_Account_Number 
Patient_Medical_Record_Id 
Patient_Social_Security_Number 
Patient_Initials 
Patient_Name_or_Family_Member_Name 
Patient_Address 
Patient_Unique_ID 
Email 
URL_IP 
Date 
Phone_Fax 
Provider_Certificate_or_License 
Provider_Name 
Provider_Initials 
Provider_Address_or_Location 
Note: Supplemental Table 8.1 Distribution of 2500 training notes Across Departments 
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Supplemental Table 8.2: Distribution of 2500 training notes Across Departments 
Department_Specialty                              Count  
 Gastroenterology                                    233  
 Obstetrics                                          225  
 Radiology                                           181  
 General Internal Medicine                           177  
 Pulmonology                                         161  
 Pulmonary Function and Bronchoscopy                 133  
 Ophthalmology                                       128  
 Obstetrics and Gynecology                           121  
 Emergency Medicine                                  117  
 Family Medicine                                     103  
 Dermatology                                          82  
 Cardiology                                           75  
 Reproductive Endocrinology and Infertility           60  
 Kidney Transplantation                               54  
 Endocrinology and Metabolism                         51  
 Urologic Oncology                                    50  
 Hepatology                                           48  
 Primary Care                                         46  
 General Pediatrics                                   43  
 Neurology                                            40  
 Orthopedic Surgery                                   39  
 Liver Transplant                                     38  
 Neurosurgery                                         38  
 Anesthesiology                                       35  
 Pediatric Gastroenterology                           35  
 Otolaryngology, Head and Neck Surgery                33  
 Radiology MR                                         30  
 Rheumatology                                         27  
 Radiology CT                                         26  
 Hematology and Oncology                              25  
 Urology                                              25  
 Lung Transplant                                      20  
 Breast Care - Cancer Center                          19  
 Pediatric Nephrology                                 19  
 Psychiatry                                           19  
 Allergy and Immunology                               15  
 Interventional Radiology                             15  
 Pediatric Cardiology                                 15  
 Geriatric Medicine                                   13  
 Lab                                                  13  
 Nephrology                                           13  
 Pediatric Endocrinology                              13  
 Pediatric Neurology                                  13  
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Department_Specialty                              Count  
 Gastrointestinal Oncology                            12  
 Physical Therapy                                     12  
 Dysplasia                                            11  
 HIV Program                                          10  
 Infusion and Transfusion                             10  
 Pediatric Oncology                                   10  
 Pediatric Rheumatology                               10  
 Gynecologic Oncology                                  9  
 Prenatal Diagnosis                                    9  
 Pain Medicine                                         8  
 Radiation Oncology                                    8  
 Anticoagulation                                       6  
 Heart Transplant                                      6  
 Nuclear Medicine                                      6  
 Pathology                                             6  
 Adolescent Medicine                                   5  
 Employee Health Services                              5  
 Pediatric Hematology                                  5  
 Pediatric Otolaryngology, Head and Neck Surgery       5  
 Thoracic Oncology                                     5  
 General Surgery                                       4  
 Genetics - Cancer Center                              4  
 Investigational Therapy                               4  
 Optometry                                             4  
 Pediatric Pulmonology                                 4  
 Plastic Surgery                                       4  
 Executive Health                                      3  
 Home Health Services                                  3  
 Orthotics                                             3  
 Pediatric Immunology                                  3  
 Pediatric Urology                                     3  
 Sleep Medicine                                        3  
 Audiology                                             2  
 Colorectal Surgery                                    2  
 Endocrine Surgery                                     2  
 Orthopedic Surgical Oncology                          2  
 Pediatric Anesthesiology                              2  
 Pediatric Orthopedic Surgery                          2  
 Pediatric Physical Medicine and Rehabilitation        2  
 Pediatric Surgery                                     2  
 Respiratory Therapy                                   2  
 STOR Immunizations Converted                          2  
 Surgical Oncology                                     2  
 Thoracic Surgery                                      2  
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Department_Specialty                              Count  
 Vascular Lab                                          2  
 Cardiothoracic Surgery                                1  
 Clinical Research                                     1  
 Craniofacial Anomalies                                1  
 Diabetes Services                                     1  
 Hospice and Palliative Medicine                       1  
 Hospital Medicine                                     1  
 Infectious Diseases                                   1  
 Interpreting Services                                 1  
 Melanoma                                              1  
 Pediatric Bone Marrow Transplant                      1  
 Pediatric Infectious Disease                          1  
 Pediatric Infusion and Transfusion                    1  
 Pediatric Occupational Therapy                        1  
 Pediatric Pulmonary Function                          1  
 Social Services                                       1  
 Support Service - Cancer Center                       1  
 Vascular Surgery                                      1  
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Supplemental Table 8.3: Distribution of Testing Notes Across Departments 
Department_Specialty                          Count  
 Obstetrics                                      95  
 Radiology                                       73  
 Pulmonology                                     71  
 General Internal Medicine                       70  
 Gastroenterology                                69  
 Ophthalmology                                   66  
 Pulmonary Function and Bronchoscopy             64  
 Emergency Medicine                              60  
 Endocrinology and Metabolism                    51  
 Obstetrics and Gynecology                       51  
 Family Medicine                                 50  
 Kidney Transplantation                          38  
 Cardiology                                      34  
 Dermatology                                     30  
 Hepatology                                      27  
 Primary Care                                    26  
 Reproductive Endocrinology and Infertility      26  
 General Pediatrics                              22  
 Liver Transplant                                20  
 Neurosurgery                                    19  
 Pediatric Gastroenterology                      19  
 Urologic Oncology                               18  
 Hematology and Oncology                         17  
 Neurology                                       17  
 Orthopedic Surgery                              17  
 Radiology CT                                    15  
 Otolaryngology, Head and Neck Surgery           13  
 Radiology MR                                    13  
 Urology                                         13  
 Rheumatology                                    12  
 Anesthesiology                                  11  
 Gastrointestinal Oncology                       10  
 Interventional Radiology                        10  
 Breast Care - Cancer Center                      9  
 Lung Transplant                                  9  
 Nephrology                                       8  
 Pediatric Endocrinology                          8  
 Geriatric Medicine                               7  
 Lab                                              5  
 Pediatric Nephrology                             5  
 Anticoagulation                                  4  
 Dysplasia                                        4  
 Executive Health                                 4  
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Department_Specialty                          Count  
 Pediatric Cardiology                             4  
 Pediatric Rheumatology                           4  
 Psychiatry                                       4  
 Radiation Oncology                               4  
 General Surgery                                  3  
 Interpreting Services                            3  
 Investigational Therapy                          3  
 Neuro-Interventional Radiology                   3  
 Pathology                                        3  
 Pediatric Neurology                              3  
 Respiratory Therapy                              3  
 Thoracic Oncology                                3  
 Adolescent Medicine                              2  
 Allergy and Immunology                           2  
 Employee Health Services                         2  
 Gynecologic Oncology                             2  
 Heart Transplant                                 2  
 HIV Program                                      2  
 Infusion and Transfusion                         2  
 Orthopedic Surgical Oncology                     2  
 Pediatric Pulmonology                            2  
 Prenatal Diagnosis                               2  
 Surgical Oncology                                2  
 Audiology                                        1  
 Endocrine Surgery                                1  
 Endocrinology                                    1  
 Hospital Medicine                                1  
 Integrative Medicine                             1  
 Melanoma                                         1  
 Nuclear Medicine                                 1  
 Optometry                                        1  
 Pain Medicine                                    1  
 Pediatric Diabetes                               1  
 Pediatric Hematology                             1  
 Pediatric Oncology                               1  
 Pediatric Orthopedic Surgery                     1  
 Physical Therapy                                 1  
 Plastic Surgery                                  1  
 Sleep Medicine                                   1  
 Social Services                                  1  
 Symptom Management                               1  
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8.2.3. Sensitivity Analysis 
In addition to Recall, F2 performance, and our primary sensitivity analysis, we were 
interested in two additional sensitivity analysis. First, we were interested in determining the 
impact of partial de-identification successes, specifically, were there instances where only a 
portion of the PHI was removed that made the changed remaining associated tokens from PHI to 
safe. An example would be obscuring part of a date (eg: 1/1/2018 → */*/2018) or most of a 
name (eg: John A Smith → **** A *****). Second, while not emphasizing Precision as a de-
identification metric, we wanted to catalog which elements of the Philter pipeline were the 
greatest contributors to precision errors to better anticipate which types of non-PHI words were 
most likely to be erroneously removed. 
 
8.2.4. Supplemental Results 
Supplemental Sensitivity Analysis One: What PHI Actually Remains after de-
identification. Even when de-identification failed to completely remove an entire PHI entity, 
approximately 20% of the time it removed enough of the entity to make it no longer recognizable 
as PHI  
 
Supplemental Sensitivity Analysis Two: Precision Errors 
The portions of the pipeline that search for names were the most significant contributors to 
precision errors.  
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Supplemental Table 8.4: Recognizable PHI Analysis (PHIlter, UCSF Test Corpus) 
PHI Category Recognizable PHI 
Age >= 90 0 
Patient_Vehicle_or_Device_Id 0 
Patient_Account_Number 0 
Patient_Medical_Record_Id 0 
Patient_Social_Security_Number 0 
Patient_Phone_Fax 0 
Patient_Initials 0 
Patient_Name_or_Family_Member_Name 6 
Patient_Address 4 
Patient_Unique_ID 11 
Email 0 
URL_IP 0 
Date 6 
Provider_Certificate_or_License 0 
Provider_Name 11 
Provider_Initials 6 
Provider_Address_or_Location 40 
Provider_Phone_Fax 45 
Supplemental Table 8.4. Recognizable PHI counts for PHIlter performance on the UCSF corpus. 
We defined “recognizable PHI” as any annotated identifier that was not PHI according to 
HIPAA after surrounding PHI was removed. There were 158 total FNs for Philter on the UCSF 
corpus initially, with 129 recognizable as PHI by human analysis after de-identification. Refer to 
the “Not Recognizable PHI” column in Supplemental Table 8.3 for detailed information on 
criteria used for determining recognizable PHI. 
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Supplemental Table 8.5: Recognizable PHI Analysis (PHIlter, I2B2 Corpus 
PHI Category Recognizable PHI 
AGE 0 
DEVICE 0 
MEDICALRECORD 0 
PATIENT 2 
DATE 0 
FAX 0 
PHONE 0 
ZIP 0 
USERNAME 0 
STREET 2 
LOCATION-OTHER 2 
IDNUM 0 
CITY 2 
DOCTOR 4 
Supplemental Table 8.5. Recognizable PHI counts for PHIlter performance on the i2b2 test 
corpus. There were 16 total FNs for Philter on the UCSF corpus initially, with 12 recognizable as 
PHI by human analysis after de-identification. 
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Supplemental Table 8.6: False Positive Count by PHIlter Configuration File Element on the 
UCSF corpus 
Filter False Positive Count 
Last Names Blacklist (lastnames_minus_fps.json) 1830 
Whitelist 1725 
First Names Blacklist (firstnames_minus_fps.json) 1236 
'filters/regex_context/names_regex_context3.txt' 649 
'filters/regex_context/initials.txt' 508 
'filters/regex/dates/mm_yy_transformed.txt' 366 
'filters/regex/addresses/hospital2.txt' 356 
'filters/regex/dates/mm_dd_transformed.txt' 301 
'filters/regex_context/names_regex_context2.txt' 252 
'filters/regex/addresses/in_city_transformed.txt' 242 
'filters/regex/ucsf_regex/ucsf_neighborhoods.txt' 226 
'filters/regex/contact/xxx_xxx_xxxx.txt' 191 
'filters/regex/salutations/post_salutations_2chars.txt' 172 
'filters/regex/dates/dd_mm_transformed.txt' 161 
'filters/regex/dates/month_name_transformed.txt' 108 
'filters/regex/dates/mm_dd_yy_transformed.txt' 102 
'filters/regex/salutations/pre_salutations_2chars.txt' 101 
Supplemental Table 8.6. Each row name corresponds directly a file process within the pipeline 
and its relative location on the software filepath. False positive (FP) counts for PHIlter 
configuration file elements with FP counts >=100. Because multiple filters matched some FPs, 
FP counts do not reflect total number of FPs generated by PHIlter, but rather the total number of 
times each filter matched any FP.  
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Supplemental Table 8.7: UCSF corpus TP/FN Counts 
PHI Category TPs FNs Recall 
Age >= 90 11 0 100.00% 
Patient_Vehicle_or_Device_Id 550 0 100.00% 
Patient_Account_Number 35 0 100.00% 
Patient_Medical_Record_Id 471 0 100.00% 
Patient_Social_Security_Number 30 0 100.00% 
Patient_Initials 721 2 99.72% 
Patient_Name_or_Family_Member_Name 1579 6 99.62% 
Patient_Address 3996 7 99.83% 
Patient_Unique_ID 652 20 97.02% 
Email 120 0 100.00% 
URL_IP 468 4 99.15% 
Date 13396 7 99.95% 
Phone_Fax 1469 45 97.03% 
Provider_Certificate_or_License 369 0 100.00% 
Provider_Name 5045 12 99.76% 
Provider_Initials 721 12 98.36% 
Provider_Address_or_Location 3998 43 98.94% 
Supplemental Table 8.7. TP/FN counts and recall per PHI category for PHIlter performance on 
the UCSF test corpus. The following annotated PHI categories were not considered PHI for 
performance evaluation purposes, and not included in performance analysis:. 
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Supplemental Table 8.8: Overall Recall Per PHI Category (PHIlter, I2B2 Test Corpus) 
PHI Category TPs FNs Recall 
AGE 7 0 100.00% 
DEVICE 12 0 100.00% 
MEDICALRECORD 721 0 100.00% 
PATIENT 1445 2 99.86% 
DATE 11880 0 100.00% 
FAX 6 0 100.00% 
PHONE 407 0 100.00% 
ZIP 143 0 100.00% 
USERNAME 91 1 98.91% 
STREET 414 2 99.52% 
LOCATION-OTHER 12 2 85.71% 
IDNUM 377 2 99.47% 
CITY 338 2 99.41% 
DOCTOR 3231 5 99.85% 
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Chapter 9 
Deep Cumulative Dosage Determination 
 
9.1. Abstract 
Glucocorticoids, one of the most common classes of steroids, are prescribed with a great 
variety of cumulative dosages, often including complex tapers, due to their wide utility across a 
large number of health conditions. Cumulative steroid use is associated with several serious 
health conditions and is also an important surrogate outcome for auto-immune treatments. 
Currently, determining cumulative dosage is done through manual chart review which is both 
time consuming and error-prone. Here, I detail the process by which deep learning can be used in 
the Natural Language Processing space to automatically determine the total cumulative dose of a 
steroid that a patient has received directly from the EHR ‘Sig’ field. 
 
9.2. Introduction 
Glucocorticoids are one of the most commonly prescribed classes of medications in the 
United States. They are essentially immune-suppressors, most common administered as pills, and 
are primarily indicated for inflammatory conditions ranging from Asthma, COPD, and allergies 
to Rheumatoid Arthritis, Tendinitis, and Multiple Sclerosis. Glucocorticoids are generally 
considered safe for short term use but long term use is associated with potentially serious risks 
including Osteoporosis, cardiovascular complications, and diabetes. For many of the health 
conditions in which they are used, these steroids serve as secondary treatments, taken during 
acute attacks when front line treatments fail. For example, the frontline treatment for 
Rheumatoid Arthritis are a group of drugs collectively known as Disease Modifying 
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Antirheumatic Drugs (DMARDs). DMARDs are designed to specifically treat RA, however if a 
patients disease suddenly ‘Flares up’, glucocorticoids may be additionally prescribed to suppress 
the entire immune system. In this way, glucocorticoid usage can also be a surrogate for efficacy 
of frontline treatments (such as DMARDs).  
Deep Learning has become state-of-art for many Natural Language Processing (NLP) 
tasks, including sentiment analysis and document classification which both closely mirror the 
task of assigning cumulative dosage, a discrete number, from a string of text.  
 
9.3. Methods 
9.3.1. Data 
Two fields were extracted for patients who had received Prednisone, the most common 
glucocorticoid, prescriptions: “Sig” and “Dosage” 
Sig fields within the EHR contain the physicians short hand written instruction to the 
patient about what dosage of the drug to take, when, and for how long, including information on 
potentially tapering the dosage taken over time.  
The Dosage field contains the volume of prednisone contained within each pill (not the 
cumulative dosage).  
The data itself varies widely in terms of sig length, complexity, and quality 
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Figure 9.1: Sig Word Count 
 
Figure 9.1: Length of sig, in words, on the x-axis. Count of the number of sigs that contained that 
word-count on the y-axis. 
 
9.3.2. Data Processing 
The clinical researchers have determined that exact cumulative dosage is less relevant 
binning the raw cumulative dosage into categories which describe levels of use. These categories 
were determined to be: ‘low’ if the cumulative dose was less than 5mg, “moderate” if the 
cumulative dosage was between 5-10mg, “high” if the cumulative dosage was between 10-20mg, 
and “very high” if the cumulative dosage was greater than 20mg.  
 
9.3.3. Gold Standard 
To assign gold standard labels, 845 charts were manually reviewed by trained clinical 
researchers and assigned one of the four labels. 25% of these, or 212 total samples were held 
aside for testing, the remaining samples were used to conduct three experiments 
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9.3.4. Base Model 
I was initially most interested in the type of data, as opposed to model architecture, that 
would best solve this type of problem. Therefore, for prototyping purposes I chose a simple 
single architecture that seemed to perform well initially on this task and multiple related tasks.  
 
Table 9.1: Pred-sigs Base Architecture 
Layer (type) Output Shape Param # 
embedding_1 (Embedding) (None, 20, 64) 18368 
conv1d_1 (Conv1D) (None, 18, 32) 6176 
max_pooling1d_1 (MaxPooling1) (None, 9, 32) 0 
dropout_1 (Dropout) (None, 9, 32) 0 
lstm_1 (LSTM) (None, 32) 8320 
dropout_2 (Dropout) (None, 32) 0 
dense_1 (Dense) (None, 16) 528 
dropout_3 (Dropout) (None, 16) 0 
dense_2 (Dense) (None, 4) 68 
Total params: 33,460 
Trainable params: 33,460 
Non-trainable params: 0 
 
9.3.5. Experiments 
1. Sig field alone into the base architecture 
2. Language model built using all labeled training sigs, then transferred to the classification 
task 
3. Dual input model using sig field and dosage 
 
For all experiments, sig length was treated as a hyperparameter.  
 
 
 143 
9.4. Results 
Table 9.2: Initial Experimental Accuracy 
Experiment Test Set Accuracy 
Sig Field Alone 70% 
Lang Model + Sig Field 68% ** 
Sig + Dosage 77% 
 
Table 9.3: Classification Report of Sig+Dosage Experiment 
 precision recall f1-score support 
0 0.76 0.93 0.84 86 
1 0.81 0.61 0.70 62 
2 0.62 0.60 0.61 35 
3 0.88 0.79 0.84 29 
avg/total 0.77 0.76 0.76 212 
 
Table 9.4: Sensitivity Analysis: Incorrect Predictions for Class “High” (2) Sig+Dosage 
  Sig Dosage Pred_class/True_Class 
34 
mg total by mouth daily take 20mg a day for 
one month then decrease by 5mg every 2 
weeks until you reach 10mg a day 
10.0 690 1        2 
52 take 5 mg by mouth 4 four times daily 1.0 706 0        2 
56 
generic for deltasone take 2 tablets by mouth 
daily 
10.0 715 0        2 
57 
mg total by mouth daily take 2 tablet 20 mg 
total by mouth for 3 days then decrease to 1 
tablet 10 mg total daily 
10.0 649 1        2 
73 
tablet 5 mg total by mouth daily 30mg d x 1 
week 20mg d x 1 week 15mg d x 1 week then 
10mg d 
5.0 642 1        2 
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  Sig Dosage Pred_class/True_Class 
106 
take 1 tablet 2 5 mg total by mouth daily for a 
total of 12 5mg 
2.5 641 0        2 
111 
mg x 5 days take 3 tabs 30mg x 5 days take 2 
tabs 20mg x 5 days then take 1 tab 10 mg 
thereafter 
10.0 696 0        2 
133 take 2 tablet by mouth every day 10.0 675 0        2 
157 take 1 5 tablets daily 10.0 598 1        2 
158 
day for 1 week then reduce to 40 mg for 4 days 
then reduce to 20 mg for 4 days then reduce to 
10 mg 
10.0 704 1        2 
161 
take 1 tablet 1 mg total by mouth daily please 
take 16 mg total per day 
1.0 708 0        2 
171 
2 16 2 22 then 55 mg 2 23 2 29 then 50 mg 3 1 
3 7 then 45 mg 3 8 3 14 
10.0 707 1        2 
177 
take 5 mg by mouth daily taking 15 20mg 
daily 
5.0 606 3        2 
188 
30mg d x 1 week 20mg d x 1 week 15mg d x 1 
week then 10mg d 
10.0 686 1        2 
Columns from left to right: ‘signature’, ‘dosage’ , ‘sample_index’, ‘predicted class label’, ‘true 
class label’. 
 
 
9.5. Discussion and Future Directions 
This is a difficult problem. Even as person with a background in clinical research, it is 
often impossible to tell what the dosage is, just looking at the sigs themselves. Examples of this 
can be seen in the Sensitivity Analysis table above. Often times context that is known to a 
clinical chart reviewer but is not present in the sig or dosage information itself is necessary to 
determine the cumulative dosage. Additionally, the writing of the Sigs sometimes appears to be a 
language puzzle of sorts, for example “take 1 tablet 1 mg total by mouth daily please take 16 mg 
total per day”. Was the answer 1mg total by mouth daily or 16mg?  
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In fact, not all of the errors were caused by the machine, throughout the development 
process we consistently found examples that the machine had labeled correctly but had been 
mislabeled by the expert human annotators. Additionally, there are pure data errors. We have 
encountered multiple sigs which clearly contain two different sigs that have been concatenated, 
probably as a result of copy/pasting by the physician or a bug within the Epic EHR system.  
Despite all of these challenges, and the relatively short amount of time that has been 
dedicated to the project so far, the initial results are quite promising. Result of the top-
performing approach are already hovering in the range of results offered by a commercial 
software company to UCSF at 6-figure licensing cost.  
The target accuracy in order to reach research utility is approximately 85%. To that end, 
next steps are fairly straight forward. First, Python scripts to identify and rectify double sigs will 
be implemented. I am also in the process of designing some ‘helper’ functions to crawl through 
the Sigs, in an attempt to provide the context known to experts but not present in the data itself. 
This helper context will be passed in as a separate input to the network. Finally, I will re-do 
Experiment Two, using all 50k glucocorticoid sigs instead of just the 800 that were part of the 
initial dataset.  
The task is difficult and unlikely to ever reach above 90% accuracy due to the inherent 
noise, errors, and ambiguity in the data itself. However, tasks such as this highlight the power of 
current deep networks in the NLP space. In the space of a few hours of development time I was 
able to achieve current state-of-the-art results that had been developed by teams of people over a 
substantial period of time using older techniques.  
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Chapter 10 
Medical Research Topic Labeling 
 
10.1. Introduction 
The NIH and other agencies are funding high-throughput genomics (‘omics) experiments 
that deposit digital samples of data into the public domain at breakneck speeds. This high-quality 
data measures the ‘omics of diseases, drugs, cell lines, model organisms, etc. across the complete 
gamut of experimental factors and conditions. The importance of these digital samples of data is 
further illustrated in linked peer-reviewed publications that demonstrate its scientific value. 
However, meta-data for digital samples is recorded as free text without biocuration necessary for 
in-depth downstream scientific inquiry. Deep learning is revolutionary machine intelligence 
paradigm that allows for an algorithm to program itself thereby removing the need to explicitly 
specify rules or logic. Whereas physicians / scientists once needed to first understand a problem 
to program computers to solve it, deep learning algorithms optimally tune themselves to solve 
problems. Given enough example data to train on, deep learning machine intelligence outperform 
humans on a variety of tasks. Today, deep learning is state-of-the-art performance for image 
classification, and, most importantly for this proposal, for natural language processing.  
This proposal is about engineering Crowd Assisted Deep Learning(CrADLe) machine 
intelligence to rapidly scale the digital curation of public digital samples. We will first use our 
NIHBD2K-funded Search Tag Analyze Resource for Gene Expression Omnibus 
(STARGEO.org)to crowd-source human annotation of open digital samples. We will then 
develop and train deep learning algorithms for STARGEO digital curation based on learning the 
associated free text meta-data each digital sample. Given the ongoing deluge of biomedical data 
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in the public domain, CrADLe may perhaps be the only way to scale the digital curation towards 
a precision medicine ideal. Finally, we will demonstrate the biological utility to leverage 
CrADLe for digital curation with two large-scale and independent molecular datasets in: 1) The 
Cancer Genome Atlas(TCGA), and 2) The Accelerating Medicines Partnership-Alzheimer’s 
Disease (AMP-AD). We posit that CrADLe digital curation of open samples will augment these 
two distinct disease projects with a host big data to fuel the discovery of potential biomarker and 
gene targets. Therefore, successful funding and completion of this work may greatly reduce the 
burden of disease on patients by enhancing the efficiency and effectiveness of digital curation for 
biomedical big data. 
 
10.2. Methods 
10.2.1. Goal 
We sought to develop two independent deep learning models with large-scale human 
curation of GEO, and we would combine that intelligence to facilitate most accurate automated 
digital curation.  
 
10.2.2. Data 
 Currently, STARGEO catalogues 1,122,750 digital samples drawn from 31,379 
experiments that can be curated. Therefore, to curate all the experiments with human curation at 
about 3 minutes (2.17 minutes for primary curation + 48 seconds or secondary curation) an 
experiment means about 20 validated experiments can be produced an hour between a primary 
and secondary curator. This proposal to develop deep learning models of human curation is 
justified because it will take about 65 days to curate all of STARGEO and validate it among two 
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curators, but only 17 days if accurate machine digital curation can make an accurate primary 
annotation, given an on-demand Upwork crowd can provide rapid biocuration validation. Given 
increased training data generally improves DL classification models. our CrADLe approach to 
annotate STARGEO with human and machine intelligence is not only feasible, but likely a 
cheaper, faster, more accurate and most importantly a much more scalable than other annotation 
efforts.  
Given large enough datasets to train on, DL has proved superior for learning patterns in 
medical imaging for prognosis of Alzheimer’s disease and mild cognitive impairment, organ 
segmentations and detection, ultrasound interpretation, etc. For computer vision applications, 
convolutional neural network (CNN) models have skyrocketed to state-of-the-art performances 
as open architectures such as Google’s Inception v3, Inception v4, and the Google/Microsoft 
hybrid Inception-Resnet accuracyrates greater than 97% that outperform humans for image 
recognition. Most recently, Google developed and validated a best-in-class DL model of diabetic 
retinopathy in retinal fundus photographs had 90.3% sensitivity and 98.5% specificity for 
detecting referable disease. Using 128 175 retinal images, which were graded 3 to 7 times for 
diabetic retinopathy, diabetic macular edema, and image gradability by a crowd of 54 US 
licensed ophthalmologists, google created a best-in-class labeled imageset to achieve state-of-
the-art performance in diagnosing diabetic retinopathy. Most applicable to this project to deep 
learn patterns of free text, recursive Neural Networks (RNNs) for sentiment analysis of free text 
pushes the state of the art in single sentence positive/negative classification from 80% up to 
85.4%. RNNs are the only model that can accurately capture the effects of negation and its scope 
for both positive and negative phrases. Given that state-of-the-art sentiment analysis of free text 
is not precise with any method, combining state of the art deep learning of NLP with a large-
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scale on demand crowd validation as we propose here to ensure precision, is both justified and 
warranted to effect intelligent machine curation of digital samples.  
 
10.2.3. Models 
For preliminary analysis, we built two different deep learning frameworks, one GeneDL 
model based on a CNN of gene expression of 26 genes, and the other Words DL model based on 
free text Recurrent Long Short Term Memory (LSTM) framework state-of-the-art sentiment 
analysis of free text. Our training set was based on STARGEO crowd-annotated samples of 1903 
breast cancer vs 1045 breast tissue controls across 41 experiments run on 26 different platforms.  
 
10.3. Results 
The original LTSM achieved 0.96 area under the ROC performance, by using word 
embeddings as the initial layer in the prediction model to explicitly learn representations in 
relation to the specific prediction task thereby utilizing every sample in the training corpus to it’s 
maximum potential and further improving accuracy of predictions. Furthermore, a modification 
of the LSTM model that included CNN features performed best with complete perormance of out 
of sample AUC. In stark contrast to the LTSM architectures for words, Gene model achieved 
only AUC of 0.81under the ROC performance. This is because of a paucity of the input feature 
space of genes given the diversity of platforms and gene configurations measured in the public 
data as only 26 genes were measures across ALL digital samples across every platform. 
Nonetheless, we selected a batch normalized, fully connected, feed-forward framework with 
dropout for predicting labels from gene expression data to take complete advantage of potential 
effect of gene-gene interactions while forcing the network to learn patterns instead of 
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memorizing them. Rectified Linear Units used for activation to prevent neural saturation and a 
vanishing gradient. During our initial research the top performing model reached 11 layers 
arranged into triple repeated blocks of full connectivity, normalization, activation, then dropout.  
 
10.4. Conclusions and Future Directions 
Deep learning approaches to medical data curation are extremely promising, already 
equaling human performance but at a fraction of the time and cost. Increasing AUC from current 
measures of approximately 0.95 up to >0.999 could potentially be achieved by ensembling 
predictors.  
 
 
 
 
 
 
 
 
 
 
 
Figure 10.1: Simple DL models to compare DL 
techniques based on STARGEO crowed-annotated 
digital samples of 1903 breast cancer vs 1045 breast 
tissue controls across 41 experiments run on 26 
different platforms. Gene DL curation model (left) 
is trained from data on 26 genes that comprises 11 
layers utilizing dropout and maxnorm for 
regularization, batchnormalization, Rectified Linear 
Units (ReLU) for activation. The simpler Words DL 
curation model uses recurrence of word embeddings 
to classify samples based on free text of arbitrary 
lengths.   
 
Figure 10.1: Topic Labeling Architectures 
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Chapter 11 
Conclusion 
11.1. The Past: A Summary 
Where my work has diverged from that of other founders in this field, it has been 
primarily on the types of problems that interest us. Many have made significant contributions to 
the automation of tasks that humans already have some competency in, such as radiological and 
pathological diagnostics, and differential diagnosis. Here they have sought to make processes 
that already work, work even better, reducing error rates and the burden of repetitive tasks. My 
own work has been driven by the motivation to create methods that might enable doctors and 
healthcare systems to systematically perform tasks that are not possible today. I find myself most 
excited by tasks primarily related to predicting, and directing, the course of future. 
Looking back at the checklist of requirements from Chapter 1 that I argued were 
necessary to establish a new field of healthcare that utilizes data on previous actions and 
outcomes to enable smarter ongoing choices; the groundwork that has been laid in this short time 
is actually quite impressive. Approaches for modeling individual patients have been identified 
and validated on the clinically meaningful task of forecasting disease activity for individuals 
with Rheumatoid Arthritis; a task for which no current clinical standard previously existed. 
Furthermore, I have shown that these models can be trained in one hospital system and still 
function effectively on dramatically patients in a different hospital system, providing evidence 
that the models were able to learn something robust and transferable about individual disease 
trajectories. I have provided simple and intuitive methods to dissect what any model has learned 
about the relationship between clinical input variables and outcomes, as well as explanations for 
model predictions on a case by case basis. I have shown how the method can be extended to 
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identify patients that are similar on the basis of how input variables, such as treatments, will 
affect their outcomes, providing a method for data-driven individualized treatment selection. 
Philter, will enable the large-scale automated learning from clinical notes, which have previously 
been inaccessible to researchers due to the sensitivity of the information within them, unlocking 
the insights of the physicians that generate them. Perhaps most importantly, I have established a 
standard for designing, recording and reporting AI-based clinical informatics studies, which will 
in turn facilitate transparency and the establishment of trust and ultimately enable the utilization 
of such models in the clinical setting. 
 
11.2. The Future: A Roadmap 
The field, of course, is still in its infancy. The exciting proof-of-concepts that I have 
described above are exactly that: proofs-of-concept. The application of modern AI to health data 
is evolving so rapidly that my own research has made my manuscripts somewhat outdated before 
they were even published. This can result in a temptation to constantly strive for improvement of 
methods in the research setting at the expense of translating and testing reasonable approaches in 
real-world clinical settings. From my perspective, the next step is obvious. We must demonstrate 
whether physicians armed with insights gleaned from AI trained on relevant patients can provide 
better care for their own patients than physicians acting alone. We need not expect dramatic 
improvements initially, incremental improvements, like interest in a bank account, when 
compounded daily eventually yields remarkable changes.  
My primary hypothesis, one that is shared by every statistician, informatician, and data 
scientist in the world, is that the more completely we sample from the true population of 
individuals to build our models, the more accurate those models will become. Said more simply, 
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humans have a lot of individual variation in every aspect, health and disease are no exception. A 
single physician, no matter how experienced or gifted is only able to see a small portion of that 
variation in their career, therefore the model that their mind builds of the disease and response to 
treatment is inherently quite incomplete. AI models built using the intersections of thousands of 
doctors and millions of patients are likely to capture much more of the true variation and will 
therefore be more robust and reliable. It follows then that the best model would be one trained on 
all of the patients in the world. While philosophically correct, this line of thinking has recently 
lead to demands among researchers for the open sharing of patient data across all institutions and 
strong criticisms of the policies currently which prevent it. Many of those fighting for the public 
sharing of health data are informaticians who are quite divorced from the intimate nature of this 
data. Many people would rather share their financial information than the health information of 
themselves and their families; and no one is arguing for the open sharing of financial data. In 
short; of course we must facilitate the safe sharing of data but first we must earn trust through 
patient engagement over the use of their data, and rock-solid protocols for how data can be 
accessed, for what reasons, and by whom.  
I’d like to part with a final thought about forests and trees. It is so easy to get swept up in 
the excitement about algorithms crunching big data to determine optimal treatments at an 
individual level (trees) that it’s tragically easy to forget that disease is much easier to prevent 
than to cure (forest). According the CDC, 90% of American healthcare spending is on chronic 
diseases, 70% of which are completely preventable with healthy lifestyle practices. In fact, the 
prevention of nearly all health conditions currently effecting the first-world can summarized so 
simply that it is almost laughable: don’t smoke, eat a balanced diet of natural foods, exercise 
vigorously in safe age-appropriate manner for an hour a day 5 days a week, sleep 7-9 hours a 
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night, and don’t sweat the small stuff. The reason that these simple practices are not followed by 
all are complex. The poor do not have access to natural foods or education about the true risks of 
the ‘typical American lifestyle’. Curing lung cancer, or developing the perfect diabetes drug, is 
just sexier than convincing people not to smoke or to eat right and exercise more; attention and 
investment dollars are allocated accordingly. Finally, humans, like nearly all other species, 
evolved in environments of scarcity; we’re naturally gluttonous when possible. Those interested 
in applying AI for the maximal possible impact on the future health of the country would be 
remiss to ignore the forest for the trees. In addition to curing cancer and finding the optimal drug, 
AI must also be used to develop methods to engage people of all backgrounds about their 
lifestyles, empower them to make healthy changes, and provide better access to healthier 
nutrition.  
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